Western University

Scholarship@Western
University of Western Ontario Medical Journal

Digitized Special Collections

1992

UWOMJ Volume 62, Number 1, Fall 1992
Western University

Follow this and additional works at: https://ir.lib.uwo.ca/uwomj
Part of the Medicine and Health Sciences Commons
Recommended Citation
Western University, "UWOMJ Volume 62, Number 1, Fall 1992" (1992). University of Western Ontario Medical Journal. 175.
https://ir.lib.uwo.ca/uwomj/175

This Book is brought to you for free and open access by the Digitized Special Collections at Scholarship@Western. It has been accepted for inclusion in
University of Western Ontario Medical Journal by an authorized administrator of Scholarship@Western. For more information, please contact
tadam@uwo.ca, wlswadmin@uwo.ca.

The UNIVERSITY of WESTERN ONTARIO

-An interdisciplinary medical science publication; established 1930Volume 62

Fall 1992

umber 1

INSIDE
THIS
ISSUE:
• Chem ical Dependency

& Mental Illness
• Coca ine Toxicity
• Designer Drugs
• Toad Licking
MAIL ~ POSTE

--

c-I'Wc_.. ...__..._ . . . . .

Bl

10109

Nln

TAY
TAYPER
lll.ftE344D
93-01 - 21

ftEDICAl JOUR Al$BCTAYJSBU IYERSITYOF NESTERN

r

Oneall
24 hours a day
Trust Maclean Hunter for exceptional paging products and services, and you'll
be accessible any place ... all the time. With almost 20 years of experience,
Maclean Hunter Paging has grown to meet our customers' needs.
We're equipped to provide
you with the most advanced
paging system and
dependable answering
services so you'll be sure
to get the message.
Make the move to
Maclean Hunter Paging.
Call us today: 1-800-387-9938

Maclean Hunter
Paging
O ur Reliability is Built-in. '

Editorial

Staff

0 n

the

Cover:
Editor
Jeffrey Politsky, Meds '94
Associate Editors
Shobhana Patel, Meds '94
Ross Mantle, Meds '95
Contributing Editors
Le Wright, Meds '93
Anne Silas, Meds '94
Ian Hosein, Meds '95
Cindy Hawkins, Meds '96
Elin Ringstrom, Meds '96
Class Representatives
Les Wright, Meds '93
David Fisman, Meds '94
James Me abb, Meds '95
Jay athanson, Meds '96
Case Study
Jane Upfold, M.D.

Artwork
Ken Alanen, Meds '94
David Fisman, Meds '94
Joe Kim, Meds '96
Caroline King, Meds '96
Advertising & Marketing
Ruth Dippel, Meds '95t
Simone Meikleham, Meds '94
Robert Ghali, Meds '96
Mary Ann McKnight, Meds '96
View-An-Ad
Mailing & Circulation
Glen Hooker, Meds '94 t
Brian Gallinaro, Meds '96
Rose Lai, Meds '96
Rai Rampersand, Meds '96
Accounts Coordinator
Anne Silas, Meds '94
Printer
Willow Press Limited

t Denotes Director

•••••••••••••••••••••••••
UPCOMING SUBMISS I ON
DEADLINES:
Winter 1993 Issue (Feature Section: Gerontology)
• Journal articles ................................................................. .. January 10, 1993
• Communiques, book reviews, & art work: ........ ............. January 17, 1993
Spring 1993 Issue (Feature Section: Ophthalmology)
• Journal Articles: .. ....... ........ .. ............. .......... .... ..... ................. March 26, 1993
• Communiques, book reviews, & art work: .......................... April 09, 1993

Counter-clockwise from the
top:
1) Arnanita Muscaria ("Fly
agaric"). These mushrooms
contain muscimol (a potent
hallucinogen), ibotenic acid
(a potent insecticide), and
muscarine (a cholinergic
agent). Used for over 3,000
years by Asian and Indian
tribes. Findings are primarily
anticholinergic because of
insecticide content;
2) Tabernanthe Iboga (Ibogaine from Central Africa).
Derived from the root; u ed
for its anti-depressant and
euphoric properties. Sometimes u ed as a substitute for
cocaine.
3) Papaver Somniferum (Op-

ium poppy of SW Asia).
Cultivated as a source of
opium;
4) Cannabis Sativa (Indian
hemp plant). Dried pistillate
used to make hashish; dried
leaves and flowers used to
make marijuana;
5) Crocus Sativa (Meadow
saffron). A colchicinecontaining plant that cause
mitotic poisoning. Toxicity
can occur after a partially
dose-dependent
latent
period associated with
ingestion of seeds, bulbs,
and flowers. Saffron ha
been used successfully for
suicide;
6) Sundry items of substance abuse (pills, syringes,
and "joints").
Cover art by Joe Kim, Meds '96

•••••••••••••••••••••••••
U. W.O. Medical Journal 62 (1) 1992- - - - - - - - - - - - - - - - - - - - - - - - - -

3

CONTENTS
Editorial
Approaches to Substance Abuse ................ ........................................ 5
Faculty News
Deans' Corner ...... ....... .... .............................................. ..... ................. 7
Hippocratic Council Notes ................................................................ 8
CBLC and LRC Update .............. ....... ................................ ............ ..... 9

Chemical Dependency
(P. 17)

Class Reports
Meds '93
Meds '94
Meds '95
Meds '96

.............................................................................................. 13

......... ............................ ......................................................... 13
.............. ......... ....................... ........................... ..................... 14
.............................................................................................. 15

Feature Section: SUBSTANCE ABUSE & TOXICOLOGY
Chemical Dependency and Mental Illness: A Psychiatric Challenge
Dr. David W. Smith .................................................................... 17
California Substance Abuse Program
Dennis Zander and Ross Mantle .............................................. 21
The Potential Value of Psychedelic Drugs,
the MPTP and MDMA Stories
Jeffrey Politsky ........................................................................... 24
MPTP&MDMA
(p. 24)

Bufotenine and the Toad Licking Phenomenon
Aron D. Ross ............................. .................................................. 31
Psychedelic Dn1g Research Update.
The Hoasca Project
Dr. Dennis J. McKenna ... ........................................... ....... 35
Ibogaine Update
Bob Sisko ........................................................................... .36
Cardiovascular and Neurological Effects of Cocaine Toxicity
Anne Silas and Dr. Rocco Gerace ............................................ 39
Problem Solving

Research Update

Thinking on your Feet ........................................................................ 46

(P. 35)

Medical Vocabulary .. ......................................................................... 47
The U. W.O. Medical Journal is an interdisciplinary medical science publication, established in 1930. The Journal is
published three times each academic year: Fall, Winter, & Spring. Subscription is $17.00 per year. All material
published in the Journal reflects solely the views and opinions of the authors of the material printed and not
necessarily the editorial staff of the Journal.
©All material published in the U. W.O. Medical Journal is copywright protected-no section of the U. W.O.
Medical Journal may be reproduced without the expressed written permission of the editorial board of the Journal..
4

- - - - - - - - - - - - - - - - - - - - - - - - - U. W .O. Medica/Journal 62 (l) 1992

EDITORIAL

APPROACHES TO
SUBSTANCE ABUSE
rugs of abuse consist of those which are entrenched in our way of life (like
alcohol and tobacco) and those which are illegal (like cocaine, heroin,
cannabis, amphetamine, etc.). Current problems associated with drugs of
abuse include failure to eradicate substance abuse, excessive morbidity and
mortality consequent to substance abuse, and the financial burden of drug-related
health problems to the health care system (see inset).
In order to gain some idea of the current approach to problems associated with
substance abuse, I spoke with Alan Ogborne, a senior scientist (programs and
services evaluation, research department) at the Addiction Re earch Foundation
(ARF) in London. Clearly, there are no hard fast solutions to the problems of
substance abuse. The ARF recently outlined some objectives to be accomplished by
the year 2000 1 • These objectives included reductions in alcohol use by 25%; cocaine
and crack use by 50%; and alcohol-related traffic fatalities to 15% (from 50%). As
well the ARF is aiming for a balanced, appropriate, and accessible treatmentservice
system. Current programs designed to achieve these goals are aimed at reducing
the demand for drugs, as opposed to the supply--supply reduction has proved
very costly and very ineffective.
Programs designed to reduce demand include those emphasizing health
promotion and education (i.e. creating an awareness of the effects of drugs) and
programs designed to treat people who require assistance and therapeutic
intervention. According to Hans Embald, director of the World Health
Organization (WHO) on substance abuse, strategies to reduce drug abuse should
be based on recognition of political and economic realities of people's lives2 • In the
past, addictive drugs have been viewed as having mystical powers to not only
induce "positive" psychologic and physiologic effects, but to siphon an
individuals' ability to make a choice as well. The WHO recommends that
programs to reduce drug abuse shouldn't focus only on the harmful and mystical
properties of drugs thereby glamourizing them, but should challenge the drugs'
"positive" effects and remove the glamour a sociated with them. These steps will
allow education to progress. Programs developed within Ontario to discourage
substance abuse include Drug Awareness Week, Server Intervention, R.I.D.E., Sober
Driver, Just Say No, and Alcohol on Campus.
Treatment facilities and programs exist which are more suitable to reduce
demand in people who have developed dependencies or are likely to. The ARF has
developed an early intervention program designed to help people who have
drinking problems but are not yet dependent on alcohol. This approach has gained
support because of a potentially high success rate, the low costs, and the prospect
for preventing more serious problems. Programs also exist to help people with
drug dependency. Programs in Ontario include Detoxification, which provide a safe,
supervised setting for drug withdrawal; Assessment/Referral, which assess people
with alcohol and other drug problems; Non-Residential, which provide treatment,
rehabilitation, and/ or aftercare; Short-term Residential, which offer structure,
intensive treatment and/ or rehabilitation for 40 or fewer days; and Long-term
Residential, such as recovery homes and halfway houses. Treatment programs for
tobacco addiction are usually offered by other organizations such as the Lung
Association, the Canadian Cancer Society, and other commercial organizations. A
number of programs now incorporate, alcohol, tobacco, and other drugs.

D
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Some facts '·' :
,. 1985 Ontario dea ths related to drug use: 20,006 (30% of total); 13,375 dea ths associated with tobacco,
6,506 related to alcohol, and 125 related to illegal drugs.
,. Leading cause of death < 35: accidents and violence (50% related to drinking); leading causes of death 35-64
include lung cancer and chronic liver disease (heavily linked to alcohol and tobacco).
,. Number of alcohol-related offenses in Ontario in 1990: 106,851; number of offenses related to illicit drugs
was 25,532.
,. Cannabis is the most freq uently used illicit drug; cocaine is used much less freq uently; crack use is rare.
,. The number of alcohol and drug treatment programs in Ontario in 1988-89 was 217; most common drug
problem in the treatment system: alcohol; percent change in the number of people treated in the addictions
treatment system from 1979-89: +102%.
,. 1991-92 gov't revenue from tobacco tax: $1,028 M (2.5% of total); revenue from LCBO profits and liquorrelated sales: $1,158 M (2. 8% of total).
,. Total health care costs to Ontario related to drug abuse is estimated at $5.5 B.
,. Indicators of alcohol and dn.tg problems in Ontario suggest a recen t decline.

Mutual aid groups, such a Alcoholics Anonymous, the Betty Ford Cente r,
Narco tics Anonymous, and Women for Sobriety also aim at helping people recover
from addiction through social support. Finally, other people and facilities offering
drug treatment include general and psychiatric hospitals, mental health clinics,
counselling agencies, and probation and correctional services.
Controversy undoubtedly exi ts as to the effectiveness of various programs. An
article by Holder et al. analyzed different treatment facilities for alcoholism based
on effectiveness, benefits, and costs. 3 Their results suggested that
residential / milieu treatment programs (e.g. Betty Ford, AA) were by far the least
worthwhile, whereas brief motivational counselling, self-control training, and
social skills training were among the best treatment modalities. Apparently many
reports regarding programs like Betty Ford tend to be based on testimonial
evidence from "program graduates" and uncontrolled studies using "graduates"
as subjects. As well enrolment in these programs is elective--applicants are chosen
based on a willingness to seek aid and self-discipline. Many drug users don't have
these characteristics.
Certainly, problems associated with drug abuse and addiction are the focus of
much effort and attention. Ultimately, the ideal aim of treatment facilities is
complete abstinence. For many people reduction in use to a non-hazardous level is
a more realistic goal. The battle against substance abuse is uphill, but current
efforts suggest forward progress.
Before closing, I would like to congratulate Ross and Shobhana, and the entire
Journal Staff for a job well done. We' ve designed a new cover utilizing school
colours and the new faculty ere t. We've also incorporated a new ection called
Faculty News to promote the Journal as a communication medium for the Faculty
of Medicine and the London Medical Community. A coordinated effort and
informative articles have helped produce a very good issue! I would also like to
welcome Dr. McMurtry as the new Dean of the Faculty of Medicine. On behalf of
the Journal I wish him good fortune, and I hope that the school profits from his
wisdom.
Q

Jeffrey Politsky,
Editor.
1) ARF Report. Drugs In Ontario. 48 pp (1990).
2) ARF Joumal21(5):1992.
3) Holder H., et al. J. Stud. A1cohol.52:517-40 (1991).
4) Ministry of Treasury and Economics. 1992 Ontario Budget. 115 pp. (1992).
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DEANS' CORNER

his marks the first effort toward what we hope
will become a regular feature in the journal.
You will note from the position of the
apostrophe in the title that the column is not just for
the Dean himself to communicate with you, but also
w ill reflect issues, plans, projects, trial balloons, and
the flotsam and jetsam that any of us in the Dean's
o ffice might feel would be of interest to the
readership. For those readers who have been awa y
from Western for a while, you may be interested to
know that the Dean's office is currently configured
into six divisions. As a result, there are Assistant
Deans for curriculum (David Hollomby), education
(Bob Barr), clinical affairs Oirn Silcox), postgraduate
education (Bessie Borwein ), and continuin g
education (Keith Paton). Besides this, we have the
Office of Health Sciences Education, better known
by its acronym, "OHSED", directed by David Lloyd .
We hope that future issues will provide a forum for
each of them to speak to you.
In this first column, it seemed timely to talk a
bit about career selection. In high school, we used
to refer to this as guidance, and, there is long
tradition at that level of trying to help students to
make informed academic decisions leading them to
the career of their choice. Medical schools never
went in much for that sort of thing, even though
the decisions that medical graduates have had to
make have been every bit as bewildering as those
that faced them when they left high school.
Students were left to lurch into their lifelong
medical careers by good luck, intuition , or
fate ... perhaps all three . Sometimes it worked;
sometimes it didn't.
Now that the rules for licensure have changed
and internship is a thing of the past, the first post
graduate year is already a streaming year which sets
the student on the path to her or his ultimate
practice pattern. This has meant that these men and
women must be well informed about the vast array
of career options open to them. This is no mean
trick to achieve by the summer and fall of fourth
year when they make their applications to post
graduate programs and prioritize their submissions
to C.I.M.S. Needless to say, this has generated a lot
of anxiety amongst students. It seems as if they
have barely been admitted to medicine before they
must start searching around for the answers that
they need in order to select the post graduate
training that is right for them. As if undergraduate
medicine wasn't stress enough already!

T

At Western, we have developed two new
initiatives to help . The first is the Glaxo Pathway
Evaluation Program. Sponsored by Glaxo Canada,
thi s program is composed of three parts. In
o v ember of third y ear, during a week long
orientation to phase IV, workshops will be held in
w hich we teach the class a methodology for making
decisions and give the students a chance to practice
it . At the workshop , we provide the important
second component of the program. Each student
w ill get a binder, really a compendium, which
contains relevant information about every specialty
practised in Canada, including Family Medicine .
This book contains details of training programs plus
a lot of practical information about income, lifestyle,
practice pros and cons, etc. The final part of the
program is to encourage students to use the
forthcoming clerkship not only to learn about
clinical medicine but also as a window on the
various career options that they can take. As they
s tart a block, they should identify the career
questions that they want answered by the time they
lea v e the service. They are encouraged to ask
r es idents and consultants to talk about their
p e rceptions about their career choice. In other
words, the clerkship should be viewed as a careerguidance experience as well as a content/ skill /
attitude learning experience.
To complement this program, we will be
launching in the new year a career fair or career
night program. (We haven't quite settled on the
format yet.) This will be targeted more at first and
second year classes and will give an opportunity for
representatives of the various specialities to meet
the students, provide them with information about
their own specialities and answer questions.
Although some have referred to this as "recruiting",
we are aiming for informality and a way to plant
seeds in the minds of students who want
information early in order to think a bit and
perhaps focus their later inquiries.
The result of all of this is that many physicians
outside and inside the faculty will be subjected to a
lot more questions from students about why they
chose their areas of practice. I encourage all to take
the time to respond honestly and thoughtfully.
Now more than ever, our colleagues of the future
are depending on us.
Q

Jim Silcox, M .D.,
Assistant Dean,
Student Affairs & Undergraduate Studies.
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HIPPOCRATIC COUNC I L
NOTES

T

h~ 1992-93 Hippocratic Council, in association
With the Meds Journal will be providing this
column to improve communication betw een
the Council, the student body, and the Faculty of
Medic ine. It is our hope that this column will
generate interest and new ideas for students both
within the faculty at Western and at other Canadian
Medical Schools.
A special welcome to the Class of Meds ' 96, and
a pat on the back to Meds '95 for a job well done
during orientation. The Fanshawe Park Picnic was
once again a great way to forget the summer! The
recent Health Sciences Pub was a huge success thanks to Liisa Honey (Social VP) and all who volunteered their time.
So, what exactly does the Hippocratic Council
do? A lot! For one, we keep Medical students in
touch with issues by representation and participation on councils at Western ( eg. UMEC, Student
Affairs, USC) and throughout the country (eg.
CFMS, the Canadian Federation of Medical
Students) . Last May, Katherine Wise (past VPExecutive), Stephanie Windsor (past Community
Relations Rep.) and Merrilee Brown (Secretary) attended a conference on the evaluation of medical
students held by the EFPO (Educating the Future
Physicians of Ontario). Recently, Lesley Horton and
Ambrose Au (External Liaison Officers) traveled to
Vancouver to attend the National Conference of the
Canadian Federation of Medical Students. The
subject of post-graduate licensure and re cent
changes in the MCCQE examination formats were
discussed. On October 16, Stephen Burnett (VPExecutive) attended a conference at Dalhousie on
Confidential Counseling and Support Systems in
Medical Schools. Both student and administrative
representatives from medical schools in Canada, the
U. S., and Great Britain attended. The issues of
confidentiality and availability of services to students were discussed as important factors in an effective support system. The Council is also involved
in the community through donations to various organizations and charities, including Med Outreach
and the London Food Bank.
The first in a series of "Brown Bag" lunches was
held on October second. Dr. R. M. Barr, Assistant
Dean of Postgraduate Medical Education spoke on
the recent changes in post-graduate licensure and
the implications of making earlier career choices.
As always, many questions were generated and
problems discussed. The Student Affairs and
Learnil}g Skills Committee presents these sessions
in an effort to address the concerns, interests, and

8

questions of students on issues which will affect
them now and in the future. Watch for posters displaying upcoming speakers, including ethics
seminars!
By the time you read this, the Car Rally,
Homecoming, and Oktoberfest will all have taken
place. Future events sponsored by the Hippocratic
Council include Tachycardia (Feb. 9-13) , a Food
Drive , and the Meds Formal (early April - ALL
YEARS AND CONSULTANTS INVITED!). Also be
sure to watch for the health sciences variety night,
"Tachycardia"- coming soon!
Janice Barkey (Meds' 95) has been appointed by
the Council to sit on the Medical Sciences
Renovation and Planning Committee to keep students updated on construction (to begin in Feb.
1993) in the Medical Sciences Building. The changes
planned will involve the Medical Students Lounge,
Hippocratic Council and Meds Journal offices,
CBLC (Computer Based Learning Center), and
Learning Resources Centre.
The members of the Hippocratic Council are
your student representatives, and greatly value
your suggestions and comments regarding
Medicine at Western. If you would like to discuss
any issues or events, or have any ideas, we encourage you to contact any member of the council :
Mark Mensour,
Ambrose Au,
Stephen Burnett,
Liisa Honey,
Ingrid Tiessen,
Merilee Brown,
Elyse Lackie,
Leslie Horton,
Ambose Au,
Mohammed Moussa,
Natalie Nimetz,
Jon Riddel,
Katie Klein,
Jeff Politsky,
Ross Mantle,
Shobhana Patel,
Greg Hancock,
David Fisman,
Debbie Peneva,
Britt Carlson,
Jason Hodge,
Janice Barkey,
Dr. John Howard,

(President, '94)
(VP Academic, '95)
(VP Executive, '94)
(Social, '94)
(Treasurer, '94}
(Secretary, '95)
(Past President, '93}
(Ext. Liason Officer, '94)
(Ext. Liason Officer, '95)
(USC Rep., '95)
(Comm. Relations Dir., '95)
(Athletic Rep., '94)
(Athletic Rep., '94)
(Meds Journal Ed., '94}
(Meds Associate Ed., '95}
(Meds Associate Ed., '94)
(Tachycardia Rep., '93}
(Tachycardia Rep., '94)
(Meds '94 Class President)
(Meds '95 Class President)
(Meds '96 Class President)
(Renovation Rep.)
(Honourary President)
Q

Mark Mensour and Stephen Burnett
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CBLC &

LRC UPDATE

Renovations
nexpectedly, this past summer the Province
announced it would provide $2.6 million in
funding through "Jobs Ontario Capital" for
renovations to the M139 area of the Medical
Sciences Building. The renovated area will provide:
three additional classrooms, eight small group
teaching rooms, a larger Learning Resource Centre
(LRC) and Computer Based Learning Centre
(CBLC), office space for the Meds Journal and the
Hippocratic Council, and a new medical student
lounge and study room. The office of Instructional
Resources will also relocate to the renovated area.
The final design has not been completed but the
anticipated start date for reconstruction of the area
is January of 1993. Students will be notified of the
exact date the area will be closed off and the
locations of the temporary sites for the Student
Lounge, Computer Based Learning Centre, and
Learning Resource Centre. Janice Barkey (Meds' 95)
is the student representative and liaison on the
planning committee and the Hippocratic Council.
Student input into the design of the area is
welcomed.

U

Nursing Student Access
Another new change in the CBLC/LRC has been
the addition of access to Nursing students. The
Faculties of Nursing and Medicine are collaborating
in the expansion of the LRC/CBLC and pooling
their learning resources for mutual student use. A
new staff person has been added by the Faculty of
Nursing to assist in the Centre. Kathryn Morton
joined the Learning Resource Centre in October of
this year and is available to provide students and
faculty with assistance in the Learning Resource
Centre.
Summer Student Projects
Two instructional resources completed this summer by Leila Kasrai, Janice Barkey and Margherita
Cadeddu are available for use in the LRC:
(i) The Rectal Exam Module provides complete
instruction on performing a rectal exam. Within the
module the slide/tape program describes the
procedure step by step and with the poster displays,
shows examples of some of the more common
lesions one may encounter during inspection. A
male anatomical model of the pelvis and pathology
specimens are also available. Finally, a prostate
exam mannequin and manual provides an
immediate opportunity for practising your skills.
(ii) The Pelvic Exam Module is composed of a
detailed instructional videotape demonstrating a

News

female pelvic exam, a female anatomical model of
the pelvis, pathological specimens, and pelvic exam
mannequins with a manual for practice.
New Programs/Materials
The following materials have recently been
added to the collection:

Computer Assisted Instruction:
"AIDS: Vignettes for Physicians";
"Cardiovascular Physiology: Lab Experiments"
(Macintosh/Videodisc);
"Epidemic in a Small Town: Introduction to the
Epidemiologic Process" (Macintosh/Videodisc);
"Human Reproduction and Development";
"HyperHistology" (Macintosh/Videodisc);
"The Impotent Patient" (Infowindow /Videodisc);
"Right to Die? The Case of Dax Cowart" (Infowindow /Videodisc);
Videotapes:
"A.I.D.S.: Fears and Feelings";
"Breaking Bad News";
"The Gynecological Teaching Assistant: Pelvic and
Breast Exam";
Mannequins:
Breast Exam Simulators;
Pelvic Exam Simulators with manual;;
Prostate Exam Simulator with manual
Slide/Tape Programs:
"Clinical Methods: The Rectal Exam";
Reference Texts:
"The Art and Science of Bedside Diagnosis";
"Atlas of Chest Infections";
"Atlas of Gastrointestinal and Hepatobiliary
Infections";
"Atlas of Infections of the Skin";
"Atlas of Sexually Transmitted Diseases";
"The Ciba Collection of Medical Illustrations"
Vols. 1-8;
"Color Atlas of Allergy Series";
"A Guide to Physical Examination and History
Taking";
"Infectious Diseases Text and Color Atlas";
"Microbiology Scope Publication Series";
"Principles and Practice of Infectious Diseases";
CD-ROM
Scientific American Medicine "Consult". This is
a subscription to a continuously updated compendium of medical information which is indexed
and searchable. The resource includes both graphics
and text. We are very pleased to be able to offer CDROM for the first time in the CBLC.
Reference texts, slide/tape programs, and computer assisted instruction on the DOS based system
of terminals are accessible to Medical and ursing

U. W.O. Medical Journal 62 (1) 1992- - - - - - - - - - - - - - - - - - - - - - - - -

9

Faculty

News

students around the clock in the LRC. Videotapes
and mannequins are currently only accessible when
the CBLC is open.
In Progress
We are pursuing funding from the GradPact*
and Foundation Western for a number of new
materials as well as Medline in the CBLC. We feel
that a Medline service would be an appropriate
addition to the centre in the near future. [Editor's
note : Third party funding is also being s ought
independently by Hippocratic Council, preferrably
for a multidisk server, licensed for network access
in the CBLC. The contact person on Council is
Ambrose Au . According to Ambrose, Western
Medicine is one of only two medical faculties in
Canada without free Medline access for students.]

Access to electronic mail for students, a standard
service for medical schools around the world who
are connected via the interuniversity Vax network,
is also on the drawing board. With this service,
students could send and receive mail to universities
around the world at low cost, with personalized
billing through a system of access codes. The
service also provides a large number of specialized
bulletin boards for exchanging information.
Q

Beth Thorstenson, CBLC/LRC Director
*The GradPact is a vehicle administered by
Foundation Western through which students about
to graduate may pledge money for the next three
years to be used as the graduating class sees fit.
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The Weight Watchers program has been developed by prominent experts
in the field of obesity, nutrition, psychology, and exercise physiology. It is
a structured, multi-disciplinary approach to weight loss that addresses the
whole patient with a food plan , a cognitive/behavioral support strategy, an
exercise program, a maintenance plan and group support.
If you would like more information, please write us at:
Doctor Information Centre
Weight Watchers
661 0 Turner Valley Road
Mississauga, Ontario L5N 2P1

na success. and success Wll
SU<ely lollo.N
• K> hande )OUrself, use )OUr head. to hande ~
use your hean
• l.'.brk to beccme. na to acqwe
• A lie may take care ct the preserc. but ~ has no future
• GoodwoiiS acl"ooEM!d bv many ac:IJ<lrl& l can be losl by ore

Section

TRIBUTE
TO DEAN
VALBERG

• IV:n lor seMCe,

SYNTEX

MOVING
TOWARDS
A BRIGHTER
FUTURE.
IDUPONTI
IPHARMA I

You don't want to Jearn that you're going
to be a parent before you're ready.
Or that through one careless moment,
you've caught an unwanted disease.
So take care. Be well informed and protect
yourself.
At Ortho, we're the experts in birth control
and disease prevention. That's why we'd
like to help make sure you learn oruy the
things you want to learn.

l!J

Take care. Not chances.

In June of this year,
Dr. Leslie Valberg
stepped down as Dean
of the Faculty of
Medicine
at
The
University of Western
Ontario after a sevenyear term.
Leslie Valberg was
born in 1930 in
Churchbridge,
Saskatchewan.
He
entered the six-year
medical program at
Queen's University in
Kingston at eighteen
and graduated with a
Gold Medal in 1954 .
He completed residency training and a
Master's Degree in
biochemistry by 1958.
After a year in England
as a Medical Research
Council Fellow, he
took a position at
Queen's for 15 years as
Lecturer. His research
included studies on
absorption and metabolism of iron, zinc,
and
other
heavy
metals. He has become
an authority on hereditary hemochromatosis.
He served as Chief of
Gastroenterology and
Director of the Clinical
u 12
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Investigation Unit at
Kingston
General
Hospital, and received
Queens' Aesculapian
Society (medical school
student
council)
Lectureship Award for
excellence in teaching
in 1966.
Dr. Valberg was
Chairman
of
the
Department of Medicine at The University
of Western Ontario
from 1975-85. In 1985,
he was selected to be
Western's new Dean of
Medicine, a very high
honour bestowed upon
a physician.
When Dr. Valberg
entered the position,
Western's
undergraduate medical
curriculum
was
organized
roughly
along
the
lines
recommended
by
Abraham Flexner some
seventy-five
years
before: two "in class"
years followed by two
"in hospital" years.
Today, the "in class"
segment has been
extended by almost
five months due to the
introduction
of
Problem-Based
Learning.
Dr. Valberg has
served the academic
medical community in
an eminent fashion for
over thirty years, seven
of those as our Dean.
Through these efforts,
his successor, Dr.
McMurtry, has a strong
legacy upon which to
build his own vision of
our medical school.
We thank Dr. Valberg
for leading us through
the last even years.
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Delegates attending the 1992 OHA Convention & Exhibition will
h.ave many opportunities to participate in educa~ sessions
planned in accordance with the overal theme '"The Future is Now:

Blueprints for Tomorrow's Hospitals" and dealing with the key
issues of Quality Management. Accountability, Employee/
Management Coopenotion and greate< Consumer Focus.
More than 300 exhibitors are also planning to participate in the
Convention, displaying for delegates the latest in hospital
equipment and services. We hope you wiD take advantage of
Canada' s largest and most comprehensive health care services,
products and equipment exhibition and visit these outstanding
displays.

For registration i-'lformation please contxt the Ontario Hospital
Associatlon (41 61429·2661 , Ext. 5600.

Ferring specializes in the re searc h,
development and di tribution of peptide
medicines. In 1961, Ferring was one of the
first pharmaceutical companies in the world
to synthesize the pituitary hormone s,
vasopres in and oxytocin, on an industrial
scale.
Ferring product are marketed worldwide.
The company 's fir t peptide introduced to
Canada wa DDA V J>@>, distributed under
licence. In June 1989, DDAVP was approved
for nocturnal enuresis and a new spray
delivery form was introduced.
Ferring Inc. was e tablished in 1986 and i
the Canadian affiliate of Ferring B,
Sweden. We are pleased that we now serve
the Canadian market directly from our
facilities in Willowdale.
We can be contacted by calling ...

1-800-263-4057

CONTINUES TO SUPPORT HOSPITAL PHARMACY

CONGRATULATIONS TO
THE GRADUATING CLASS
FROM ORGANON CANADA
LTD./LTEE

Corporate Office
145 Jules-teger Street
Bouchefville. Quebec, Canada
J48 7KB
I5 I 4) 596-{)()()()
Canada: 1-8()().361·3062
Fax: (514) 59b-0003

Mississauga/Ontario
6600 Goreway Drive
Mississauga, Ontario, Canada
l4V IS6
(416) 676-0006
Canada: Hl()()-263· I 780
Fax: (4 I 6) 670-0486

Organon Canada Ltd./Ltee
565 Coronation Drive
West Hill, Ontario
MIE4S2
Bus: (416) 284-6131
Fax: (416) 284-6768
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by Les Wright

reetings all! Since fourthyear electives have tossed
our class across the city,
country, continent, and planet,
there is little local Meds '93 news
to report this time around. By
the time this little missive is
published, our mates will have
returned from
no doubt
stimulating experiences in such
places as England, Hawaii, Los
Angeles,
New
York,
Massachussetts,
northern
Quebec, Toronto, Kingston, and
London, Ontario. Hopefully, all
will make it home safely for class
on November 30.
Of course, the spectre of
internship and its concomitant
application process dogs senioryear medical students no matter
how much they try to hide. For
those of you who have had early
interviews, I hope they went
well. For those of you awaiting
responses, I wish you all the best.
Incidentally, for anyone who still
has
not
sorted
it
out,
postgraduate education in
Ontario as of June 1993 can be
described as follows: there is no
such thing as a "two-year
internship" -there never was.
One must pursue residency
training of at least two years
duration leading to certification
either by the Canadian College of
Family Physicians (in the case of
Family Medicine training) or the
Royal College of Physicians and
Surgeons of Canada (in the case
of specialty training) prior to
being eligible for licensure. To
this end, most Canadian faculties
of medicine are offering Postgraduate-Year-One positions in
Family Medicine and Royal
College specialties that may or
may not resemble the rotating
internships of old. Pursuing
Family Medicine training as a
"two-year internship" in order to
be licensed prior to entering

G

Royal College specialty training
is being highly discouraged on
economic and ethical grounds.
An informal survey leads one to
believe that man y in our class
have been so discouraged: most
of us who are Royal College
specialty-bound are going where
the money is and applying directly to Surgery, Psychiatry,
Internal Medicine, Paediatrics, or
whatever. This is obviously quite
a change in class sentiment
compared to six months ago, and
should hearten those who
genuinely wish Family Medicine
residency positions for the
purpose of becoming primarycare physicians. Hopefully, everyone will get what they wantfor now.
A return to the lecture hall,
after an eighteen-month-long
hiatus, awaits us on ovember
30, 1992. I understand that this
first
day
includes
a
COMPULSORY
orientation
session that all MUST attendno skipping without a darn good
reason. And, no, sticking around
a Fiji beach for an extra day or
two to study " photo-dermatology" is NOT a good
enough reason. See you all
there!
A look into the Meds '93
crystal ball reveals some
interesting goodies in store over
the next few months. Among
them: internship interviews,
Tachycardia,
more
exotic
electives, CIMS Match Day (a
time of great joy or great sorrow,
depending on your point of
view), a little quiz over two days
called the MCCQE Part 1
(incorrectly referred to by many
as simply "The LMCC"), and, if
one is good, Graduation Day, a
magical moment that will
commemorate four (or five or
seven) of the best years of our
lives. Good luck to all, and I will
keep you posted in these pages
of more class developments as
they unfold.
Q
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5
by Justin Amann

irst of all, welcome back everybody! We all made it
back after our very varied
summers. Some traveled, some
worked, some did electives, some
watched TV. (Sean), and some
got married (Caroline, Jon,
Naz ... congratulations!
Any
more volunteers- Nina?)
Some rapid fire news: Burke
is having a baby, or at least that's
the scuttlebutt. (Personally, I
think Judy deserves some credit
too.) Last week he showed the
class an ultrasound of the baby
Baird at 14 weeks. It was giving
Dad the finger. Burke will be
only the second father in the
class. (Brian is already a Dad to
all of us.)
Last week, two of our classmates reported a Kamyar sighting. In fact, this has been happening with increasing frequency, and renowned English
UFO investigator Rory Tate predicts even greater frequency as
clerkship begins.
Jon Riddell claims he met
Elvis over some beers at the Grad
Club. He also claims our men's
hockey team is going to win the
championship this year. Only one
of these claims is likely correct.
How many of you pick Elvis?
About a dozen of us wrote
Part One of the American Board
Exams back in September. A
bargain at $200 to have your ego
bashed in the city of your choice:
Detroit, Ann Arbor, Boston or
Montreal. Only Norm (my new
hero) returned with tales of anything but despair.
Leila and Margherita organized a program this fall to educate high school students on the
risks and benefits, hows and
whys of sex. A bold move, taking
frank talk about sex into high
schools in London. Congratulations to you two and to all
who participated.

F
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Steve Lai (Superguy) is reported to have superhuman
strength. This closet athlete is
now a " beast at large" after
slugging home runs in intramural baseball games and also has a
contract offer to be the Dallas
Cowboys' new QB (it's true!).
Oktoberfest saw more reputations fall this year.
The Meds soccer team, Team
Dartos, finished the season 5-0,
and is aiming for a second
straight championship. Good
luck in the playoffs.
During the Blue Jays' run for
the World Series, study time took
as big a beating as Atlanta and
Oakland combined. UMEC, in a
shining display of magnanimity,
has agreed to lower the pass requirement for the upcoming ICC
exam by 2% per playoff game
watched, plus an extra 5% for
anybody who drove to Toronto
for game 5. Dr. Haase has been
usurped by Roberto Alomar as
honourary
class
president.Finally, clerkship is almost
upon us. Psych yourselves up,
it's like a real job. You gotta be
there everyday! Use all the resources at your disposal. And
remember: it's more than a job,
it's slave labour. So enjoy it!
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by James McNabb

W

elcome back, kids. I
can't tell you how
thrilled I was to see
everyone arrive back to school
with smiling faces and refreshed
minds in anticipation of what is
sure to be a most exhilarating
and inspirational experience in
2nd year Medicine. I'm relatively
new to this article-writing thing,
but, in my time away from a
hectic academic schedule and
volunteer work down at the
mission, I have attempted to as14

semble a brief account of the recent events of this young school
year. Please note at this time that
this article is being written from
the standpoint of one medical
student and does not necessarily
represent the opinions held or
the events being partaken in by
the entire Meds '95 class.
That said, I would like to extend heartfelt congratulations on
behalf of the entire class to Jeff
Spence and Nicole Desmarais.
Nicole wed this past summer
and Jeff recently witnessed the
birth of his firstborn son. Best
wishes also to Martin McFarlane
and Donika, and to Ambrose Au
and Lydia who have announced
their engagements to be married.
Congratulations folks! [Editor's
note: Felicitations to the author
and Ms. Andrea "But-we're-notliving-together" Brkovich are
also in order, it's their ten month
anniversary. Knock yourselves
out.]
Turning now to events in
which i t might be considered
ethically and morally correct for
the whole class to participate, the
first off was Disorientation
Week. Apparently all went well
as our v olunteer staff assisted
the first years in getting accustomed to their new surroundings. A l though they tried, the
Meds '95 crew didn't quite seem
to have the ingenuity required to
surpass the former year's artistic
prowess in 0-week T-shirts. But
alas, who can be expected to top
such a culinary coup in fashion?
Thanks once again, Meds
'94 ... with bacon.
The Fanshawe Picnic was
next. An annual get together
that generally provides entertainment of mammoth proportions. There were, however, some
changes to the picnic this year,
briefly: the 1st year class cheated
their way to victory in the boat
races against the 2nd year class
instead of the traditional vice
versa, D. J. music was provided
instead of Rockin' Ramsay and

his All Girl Orchestra, and
professional bartenders were
hired in order to minimize
financial loss from handing out
free beer to free-loading 2nd
years. If only the two hired bar
girls had attended those classes
at bartending school where they
would have been taught t hat
kegs, unlike fine wine, need not
be tapped prior to consumption
in order to breathe ...
Fanshawe was soon followed
by war games. Although present
in smaller numbers this y ear
(thus forcing our medical heroes
into battle against a squad of
gun-happy weekend warriors
from the Police Force instead of
against one another) our platoon
was able to prove victorious. The
win can be attributed to many
brave souls, not the least of
which was an overly bunker-aggressive 3rd year (physician, heal
thyself), as well as the leadership
strategy and courage above and
beyond the call of duty exhibited
by our fearless, armed forces
trained, Thomas "Magnum"
Hurley. Conspicuous in their
absence were the female
brigades, led by Jen Green. although they were sorely missed,
we did understand when we
were informed they had been
hired by a secret government
task force in combination with
the CIA and the Green Ber ets.
Our thoughts are with y ou,
ladies - bring home those
P.O.W.s.
The last event which must be
recounted is Oktoberfest. Two
Murphy's Line school buses
were responsible for transporting our thirsty folk to the
Concordia Club in Kitchener.
Thankfully, sing-songs were cut
short with 47 bottles of beer remaining on the wall and, hey, the
bus driver had sped up a little
bit. As the evening wore on, no
one was sure whether this was
merely an opportunity for some
guys and gals to get together for
a few drinks, or a fo r ced
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impromptu version of "The
Young and the Restless" by Das
Fuhrer for a few of the med
school couples. Most had a great
time regardless - who needs to
have sex for the next month
anyway? Oh, by the way, Brian
Bell was successful in defending
his Murphy Bus Lines Wrestling
title, and, in his kind hearted
manner, has decided to donate
his winnings to the Oktoberfest
Illegitimate Child Fund as well
as to Sketchely Cleaners for
Hart's jacket.
Well, I've just looked at the
time, and appear to be woefully
behind in my 3rd revision study
schedule. Good luck to one and
all during exams, and we hope to
see you all at those well deserved post-exam celebrations.
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by Jay Nathanson
o this is medical school. For
an overwhelming majority
of us, the year began (and
for some of us, remains) as a
non-stop celebration of the
detoxifying marvels of the
human liver. After a host of
orientation activities, including a
class barbecue, a party at the
Graduate Club, a pub at the
Rideout, a sports day in Gibbons
Park, a beach day in Grand Bend,
and a picnic in Fanshawe Park,
we were getting acquainted with
each other. Special thanks to the
class of '95, and especially Britt
and Jeff, for making orientation
such a success.
With the commencement of
classes, the revelry and merriment continued unabated. Our
class was now starting to feel
very comfortable together, and
we met for a Star Trek season
premiere party and movie
nights. By the time that the
Health Sciences Pub rolled

S

around, it was hard for us to believe that we had known each
other for such a short time.
Within weeks, however, we
had moved on to more cerebral
pursuits, and were faced with
several serious medical dilemmas: Welsh-Allyn or Heine?
Littman or Tycos?
Every
October, the instrument companies, smelling the new and not
quite yet debt-ridden medical
students, visit Western to elucidate on their products' distinctive features and inform us
where the other brand is lacking.
We could look forward to
spending over six hundred dollars on various "toys" that, for
the most part, will rarely be used
and, when needed, can be found
in abundance in any hospital.
The first few weeks of classes
also brought with it a very important lesson: if you're in
medicine for the money, start
writing textbooks.
Then we started dissections.
Six medical students, dressed in
(initially) white lab coats, trying
to ignore the smell, exploring the
wonders of human anatomy,
hunched over a cadaver, engrossed in the task of finding one
nerve, vessel, or node among
thousands. The ultimate in bonding.
Finally, class elections were
held. Jason, who had been on the
campaign trail since the very
first day (if not before), was
elected Class President. As well,
Farhan was chosen to be our
Vice-President and April was
elected as Treasurer.
Well, that's the way it is. I
hope everyone has a great first
trimester (or had a great
trimester - depending on how
long it takes for the Journal to
come out), and I'll see you next
Journal.

Reports

he U.W.O. Medical
Journal is an interdisciplinary medical
science publication. The
Journal was established in
1930. Since that time the
Journal has always published
original articles of topical or
historic relevance.
The continual maintenance and improvement of
a high standard of literary
excellence in the U.W.O.
Medical Journal requires a
great deal of commitment on
the part of the Journal staff.
Clearly, however, effort alone
is not enough! Rising
operating costs make the
accumulation of external
funds an essential factor for
the successful operation of
the Journal.
One important method to
obtain additional financial
resources
is
through
donations. The Journal
encourages all post-graduate
readers (including alumni) to
make a commitment to the
U.W.O. Medical Journal in
the form of a cash donation.
These contributions may be
$20, $40, $60, or more. Sums
of $40 or more result in the
designation of the donator as
a patron of the U.W.O.
Medical Journal.
Thank you kindly for
your continued support.

T

The U.W.O. Medical Joumal

N.B. Donations are tax
deductible; receipts will be
forwarded.
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The Only Advantage
You Need
The Medi-Dent Advantage Card sets you apart
as a member of an elite group. Medi-Dent
Advantage Card members have access to a
pre-approved line of credit for the purchase of
equipment, furnishings, leaseholds etc. in a quick,
simple and easy to use process. Contact your
Medi-Dent representative for full details

Mecli-Dent
A division o{Commcorp Finandal s~rvias Inc.

Personalized Lease Financing
And Financial Services

Feature
Section
This month's Feature Section is
Substance Abuse & Toxicology.
Articles range from the obcure to the
more general.
On page 17 is Dr. David Smith's
discussion of co-presentation of chemical
dependency & mental illness. Aron Ross
writes about the obscure practice of
toad licking (p. 31). Anne Silas and
Dr. R. Gerace present the effects of
cocaine toxicity (p. 39). Plus
a drug research update
and more!

We're working for you.
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We represent Parke-DiMS ... a
compartf of more than 600 people
ded icated to your health and
well-being.
We are the people who
deYeloped and produce medications
that help to control epilepsy. We are
the ones who make cardiovascular
agents that help to grve people wrth
heart disease amore !JOOlising future.
We Mn make products that help you
rest more comfortably when you

You also may be happt to know
that there's something exciting going
on 1n our laboratories right now that
we expect to be our greatest
contribution to your healthcare so
far. You'll be hearing about it very,
very soon.
Here's to a healthier Canada.
Here's to a healthier you.

comedc>Nnwrthacold.
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CHEMICAL DEPENDENCY AND
MENTAL ILLNESS:
A PSYCHIATRIC CHALLENGE
David W. Smith, M.D.

I T RODUCTIO N
n the study of chemical dependency, the term
"comorbidity" refers to the simultaneous
occurrence of psychiatric disorders and alcohol
or drug abuse disorders. Affected persons are
commonly referred to as "dual-diagnosis" or "dual
disorder" patients. The "Vision for the 90's"
submitted to the Ontario Government highlighted
the need for improved assessment and treatment of
the dual-diagnosis patient. Estimates place the
number of dual-diagnosis patients in the province
at 250,0009 • Review studies show that 40 percent or
more of psychiatric inpatients have a chemical
dependency diagnosis as well as a psychiatric
diagnosis 9 • 10 • A recent study at the orth Bay
Psychiatric Hospital revealed that 56.7 percent of
psychiatric in patien ts satisfied the criteria for
chemical depende n cy according the MAST
[Michigan Alcohol Screening Test]. In spite of the
frequency of drug abuse and drug addiction among
the psychiatric patient population, most psychiatric
units in general hospitals and admitting units in
provincial hospitals d o not routinely assess for
chemical dependency, or provide structured
intervention.

I

CASE VIGNETTE
Don B. is a 30-year-old male alcoholic. He
reports that he was a slow learner in school and was
labelled as a hyperactive child. He began abusing
alcohol as a teenager and reports that he drank to
"feel normal". From the age of 18 to 28 Don entered
detoxification centres more than fifty times. He
completed six alcohol treatment programs. Don was
never able to remain sober for longer than six
months in spite of his AA (Alcoholics Anonymous)
ABOUT THE AUTHOR:
Dr. David W. Smith completed his medical education and psychiatric
residency at the University of Gllifomia at Los Angeles. He is board certified
in psychiatry by the American Boord of Psychiatry. Dr. Smith has held a
number of academic positions, which include: Medical Director of tile St.
Thom12s Psychiatric Hospital's Addiction Rehabilitation Unit, Assistant
Clinical Professor of Psychiatry at the University of Western Ontario, a
member of the Dual Disorder Committee of the American Society of
Addiction Medicine, and faculty member of The Sdwol for Addiction Studies
of the Addiction Research Foundation .

attendance where he obtained a sponsor and
worked on the 12 steps towards recovery. Don
reported that he experienced rapid mood swings
when sober. He reported "My mood would go from
the floor to the clouds in a rna tter of hours."
Assessment at the St. Thomas Psychiatric Hospital
Addiction Unit, determined that he might be
suffering from an atypical affective disorder and he
was s tarted on Lithium Carbonate. Li thium
treatment has allowed Don to enjoy long-term
sobriety for the first time. After two weeks of
Lithium therapy he reported,"For the first time in
my life I feel like an earth person."
Don B's story illustrates the tragedy of delayed
diagnosis. Chemical dependency practitioners and
psychiatrists must examine individuals who
frequently relapse more closely in order to
determine possible psychiatric disorders.
I M P EDIMENTS TO PR O PER A D DICTI O N
ASSESSMENT
Historically, drug addiction was not felt to be a
distinct disorder. Until 1968, diagnostic nosologies
did not allow for a separate addiction diagnosis
classifying alcohol addiction and drug addiction as
subtypes of sociopathic personality disorders 7 • In
spite of diagnostic clarification of addictive
disorders in the DSM-111-R, practitioners continued
to believe that treatment of a patient's mental
disorder would automatically cure the chemical
dependency. The professional community now
realizes that each disorder requires treatment.
Chemical dependency education was not a part
of the curriculum of many medical schools until
quite recently. University psychiatric departments
have typically involved themselves in chemical
dependency research. Psychoanalytic thinking
continues to interfere with the understanding of the
disease of chemical dependency. In add ition to
being better trained in assessment techniques,
physicians need to become aware of the importance
of the self- help community. AA, A[narcotics
anonymous] Alanon and Adult Children of
Alcoholics groups are critical to recovery.
Diagnosis of a psychiatric disorder based solely
upon the presenting symptomatologt 2 occurs too
often in the mental health field. Physicians
commonly review the outside psychiatric records of
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patients admitted to an addiction unit and to note
numerous psychiatric symptoms which lack
documentation of the temporal relationship
between the symptoms and drug or alcohol use.
Alcohol and drug histories are absent from many
files . Patients are diagnosed incorrectly and given
antidepressant medication or antipsy chotic
medication unnecessarily.

IMPEDIMENTS TO PROPER MENTAL HEALTH
ASSESSMENT
In addition to impediments in the assessment of
addiction, negative attitudes and la c k of
information have prevented addiction professionals
from making adequate mental health assessments.
Addiction treatment professionals are frequently in
recovery themselves, and tend to promote the form
of treatment that was helpful for them. This usually
involves a strong 12-step AA/ A app r oach.
Although a strict 12-step approach is critical with
some patients, the dual-disorder patient has caused
the addiction treatment community to become more
flexible in its approach. For example, the addiction
field has had to re-examine its commonly-held
belief that all drugs are bad drugs. AA has clearly
stated its position in a 1984 publication entitled
"The AA Member-Medication and other
Drugs"[Alcoholics Anonymous 1984; 9 ]. The
pamphlet states;"lt becomes clear that just as it is
wrong to enable or support any alcoholic to become
re-addicted to any drug, it's equally wrong to
deprive any alcoholic of medication which can
alleviate or control other disabling physical and/ or
emotional problems." 13 •
Addiction professionals must understand that a
relapse to chemical dependency may not be the
result of the patient's failure to "Work the
program." In the case of the dual disorder patient, a
relapse to chemical dependency could result from a
relapse of the patient's mental illness. Failure to
attend self help groups should not always be seen
as a resistance to recovery from chemical
dependency. For example, many months may be
needed for a patient with a generalized anxiety
disorder with panic to feel comfortable in a group
setting. Given the heterogeneity of the dualdisorder population, individualized treatment
planning is essentia 14 • Traditionally, individualized
treatment planning was frowned upon and was
seen as evidence of the patient attempti ng to
manipulate the addiction treatment system. There
are still treatment programs where indi v idual
sessions are discouraged. Patients suffering from
Post-trauma tic Stress Disorder from incest, or
patients with panic disorder, are unlikely to talk
about their experiences in a group until they are at
18

ease individually. The dual-disorder patient
generally does poorly in a treatment setting that ,
places the same expectations upon on all patients.
~

PRACTICAL APPROACHES TO ASSESSMENT
Before making a psychiatric diagnosis on a
patient with a chemical dependency an
understanding of the following principles: the
acute, chronic and withdrawal effects of the
patient's drug or drugs of choice; common
symptoms of protracted withdrawal, and the stage
of recovery that the patient is in . Most studies
suggest that drug abuse does not cause major
mental illness [excluding drug ind uced mental
disorders], but either exacerbates it or hastens its
onset 11 •
An accurate psychiatric diagnosis cannot be
made while the patient is under the influence of
alcohol or tests positive for illicit drugs in the urine
or blood . Serious consideration of a psychiatric
diagnosis should not be undertaken for at least two
to four weeks after detoxification. If the psychiatric
symptoms worsen in spite of abstinence, it would
be more likely that an underlying psychiatric illness
is present.
Gorski has described the recovery process from
chemical dependency in stages6 • The pretreatment
phase is characterized by the patient denial of the
presence of addiction. Unless there is a documented
period of abstinence during which psychiatric
symptoms were present, a psychiatric diagnosis
during this period is inappropriate. Detoxification
or stabilization is marked by psychiatric and
physical symptoms induced by drug or alcohol
withdrawa 18 • Withdrawal from alcohol, stimulants,
sedative/hypnotics, marijuana or opiates produce
unique mental status changes that mimic major
mental illness.
Alcohol withdrawal can cause agitation, visual
hallucinations and severe depression. The agitation
and hallucinations should cease by the end of the
first week of abstinence; depression, however, can
persist for weeks. If the depression worsens beyond
the two to four week period, treatment of the
patient with antidepressant medication may be
necessary.
Stimulant withdrawal, [i.e., cocaine and
amphetamines] produces depression, lethargy,
insomnia and occasionally a paranoid psychosis.
The paranoia induced by cocaine rarely lasts longer
than forty-eight hours, whereas it may last for
several weeks in the case of amphetamines. Urine
screening is beneficial in clarifying the etiology of a
paranoid psychosis.
Sedative/hypnotic withdrawal produces
agitation, irritability, insomnia, emotional lability
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and depression . The syndrome of protracted
abstinence
is
particularly
evident
in
sedative/hypnotic withdrawal 14 • Protracted
abstinence is a central nervous system abnormality
characterized by neural hyperexcitability, altered
thyroid function, poor visual spatial perception and
central neurochemical receptor alterations.
Protracted abstinence can last for weeks to months
after the acute withdrawal has ceased. Clinically,
protracted withdrawal is evidenced by insomnia,
anxiety, depression, memory disturbances and
irritability. Although this syndrome has been
associated with all addictive substances, it seems to
be most pronounced with alcohol and
sedative/hypnotics. Symptoms of protracted
withdrawal are frequently episodic whereas the
symptoms of an emerging mental illness are
consistent and persistent.
Opiate withdrawal produces agitation,
restlessness, insomnia, depression and emotional
lability. Withdrawal from cannabis can produce a
similar syndrome however the symptoms are less
pronounced. Unique to marijuana is the prolonged
time that it is stored in body fat. In chronic
cannabis smokers the withdrawal period could last
for four to six weeks 15 •
The next stages of recovery are early, middle,
and late. Early recovery is marked by a strong focus
on relapse prevention and adapting to a sober
lifestyle. Depressions are common during this
period as patients take inventory of the effects that
addictive chemicals have had on their lives. These
depressions, however, are frequently situational.
Middle recovery is characterized by the
development of a balanced lifestyle. Late recovery
is characterized by development of healthy self
esteem, personal growth and healthy living.

Section

and stop their antipsychotic medication. Patients
must then be educated about their illness.
Additionally, with respect to sobriety and recovery,
patients become more aware of uncomfortable sideeffects from antipsychotic medication. Clinicians
should be sensitive to this problem and be willing
to make reasonable adjustments in dosage.

AFFECTIVE DISORDERS
A common problem encountered in this group
of patients is trying to convince them that
medications for affective disorders (antidepressants
or Lithium Carbonate) do not produce physical
dependence. Twenty-five percent of alcoholics
suffer from major affective disorders 8 • Studies
reveal that comorbid depression predicts poor
vocational functioning, more substance use, and
greater dysfunction.

GENERALIZED ANXIETY DISORDER
Ten to twenty percent of alcoholics suffer from a
generalized anxiety disorders. Typical patients with
alcohol dependence and generalized anxiety
disorder develop alcoholism as a byproduct of their
attempt to ease anxiety. Practitioners must be aware
of the extreme physical discomfort these
individuals' experience during recovery.
Pharmacological treatments, along with behavioral
interventions, are thought to be the most effective.
As stated previously, these individuals will require
a lot of time before they will participate in group
discussions. Patients with generalized anxiety
disorder may do best in individual addiction
intervention and treatment.

POST-TRAUMATIC STRESS DISORDER
TREATMENT ISSUES

The most common psychiatric diagnoses
coexisting with a diagnos is of addiction are
schizophrenia, affective disorders, post-traumatic
stress disorder, generalized anxiety disorder and
antisocial personality disorder. These disorders
cannot be successfully treated if the patient is using
mind- altering chemicals.

SCHIZOPHRENIA
In my experience of working with patients with
schizophrenia, two unique issues emerge. Patients
with schizophrenia enjoy the positive atmosphere
recovering in the community. There is an
expectation of recovery that does not exist in most
mental health settings. This sometimes causes
patients to want to shed the mental illness label

Symptoms of Post-traumatic stress disorder
frequently appear spontaneously as recovery
progresses. Most addiction specialists suggest
waiting for several months before engaging the
patient in "uncovering psychotherapy." The
patient with Post-traumatic stress Disorder is an
exception. If the patient is experiencing flashbacks
of the incest perpetrator, nightmares, severe
emotional lability, depression, and anxiety, to a
degree that causes them to be dysfunctional, then
therapy should not be postponed. Depending upon
their symptomatology, patients may require
antidepressants and psychotherapy. Recovery
support groups can be most helpful with these
individuals. If the patient is female, she may not
feel comfortable in mixed AA/NA groups and
may prefer to attend Women For Sobriety
meetings.
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ANTISOCIAL PERSONALITY DISORDER

REFERENCES

A patient who presents for addiction treatment
with a diagnosis of Antisocial Personality Disorder
should be carefully reviewed for accuracy of
diagnosis . .Knowing whether the antisocial disorder
predated the chemical dependency or occurred as a
result of it is important. Antisocial Personality
Disorder has been found to be present in four
percent of males and less than one percent of
females in the general population. Among alcohol
abusers, however, the incidence increases to fifteen
percent of males and ten percent of females?.
Longitudinally, the diagnosis has been shown to be
unreliable. MMPI [Minnesota Multiphasic
Personality Inventory] abnormalities frequently
return to normal in this patient population after
long-term sobriety. The therapist must be careful
not to allow his or her anger with the patient to
prompt a non-therapeutic decision to be made.
Many patients demonstrating Antisocial Personality
have been victims of severe child abuse resulting in
them having frequent conflicts with authority
figures. Clear therapeutic contracts with these
patients which contain the therapist's expectations
regarding attendance at counselling sessions, self
help groups and drug testing is critical. In instances
where there is unresolved anger, depression or
trauma concerning childhood issues, indi idual
psychotherapy may be indicated.
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Patients with a dual-disorder of chemical
dependency and major mental illness represent a
challenge to the treatment philo ophies of the fields
of mental health and addiction. An understanding
of each area is essentia 14 • Without the development
of an integrated approach to the treatment of this
patient population, unnecessary delays in diagnosis
and treatment will continue to occur, resulting in
unnecessary suffering.

P11PHARMACEUTICALS
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Dennis Zander, Meds'94 & Ross Mantle, Meds '95
he five day "Professional in Residence
Experiential Program" offered at the world
famous Betty Ford Center in Palm Springs
California was the beginning of a new approach to
substance abuse for both of us this summer. The
centre was founded in 1982 by Mrs. Ford, former
First Lady of the United States. She was also a
former alcoholic and drug addict. Based on her
experiences in a US Navy treatment program, Mrs.
Ford was inspired to create a new way of treating
civilian substance abusers outside of the hospital.
Since 1982, 14,000 individuals have graduated from
the program and the Center has become recognized
worldwide. The trendy Palm Springs location and
$11,000 (US) price tag for a one month stay have
made this desert enclave the subject of much
National Enquirer lore, since Elizabeth Taylor and
other well known Hollywood figures have been
admitted over the years. In fact, the cost of
treatment at the Center is in the lower half of the
price range available for similar programs across
the United States. Further, less than 1% of clients are
celebrities. In addition, $250,000 (US) in financial
aid is available each year to those in need.

T

"Betty Ford"

DRUGSTORE

OFFERING

FREE
DELIVERY
SERVICE ON ANYTHING WE SELL
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For the alcoholic or addict, both inpatient and
outpatient options are available. A comprehensive
aftercare program following admission and a family
program which takes place during the patient's stay
are standard and included in the fee . The Center
strongl y encourages the families of sub s tance
abusers to become involved in family rehabilitation
to decrease the likelihood of relapse upon return of
the abuser to the home environment.
The four week inpatient program is highly
structured with therapeutic activities planned from
6 AM to 10 PM every day. The patients' schedules
include group therapy, art therapy, chores, exercises, lectures, Alcoholics Anonymous (AA)
meetings, meditation, and some time for socializing.
The inpatient centre consists of three single sex
units and one mixed unit with twenty beds in each.
As part of an attempt to keep patients focused on
treatment, diversions such as novels, musical instruments, electronic devices, clothes, telephone
conversations, or other diversions are either not
allowed or kept to a bare minimum. Also, re idents
are not allowed to socialize with patients in other
units. Dress and conduct codes are conservative and
enforced with threat of dismissal. Despi te the
restrictions on individual freedoms and activities
within the Center, the doors are not locked and any
patient may leave at any time and receive a partial
refund. evertheless, the large number of rules
create a certain "us and them" sentiment among the
patients which contributes to their camaraderie and
is a constant source of sardonic humour. ew
patients are continuously introduced to the unit as
graduates are discharged. ewcomers are therefore
able to witness other patients in their unit at all
stages of recovery and can gain inspiration from
those preparing to go home. Importantly, the enior
"inmates", as they sometimes call themselve , also
gain sell esteem from helping newer patients adjust
to the "system."
The outpatient program is identical t o the
inpatient program except that patients return home
in the evenings instead of staying in the unit. As
well, the cost is less. The cost of both the inpatient
and outpatient programs include flight arrangements and hotel accommodation for one family
member in the week-long family treatment program. Additional family members are encouraged
to attend, but must pay for their own expens s. The
family program attempts to provide close relatives
insight and therapy into their family member 's (and
perhaps their own) addiction . Since patients'
families are usually dysfunctional, either resulting
in or from the patient's addiction, the Center
encourages extersive aftercare.
A unique feature of the Center is the
"Professional in Residence" program. The program
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is an opportunity to learn about the Center and to
actually participate in treatment for 5 days. The
Center provides a travel stipend and free
accommodation through donations and gra nts
designed to promote "Aunt Betty's" treatment
philosophy. Police officers, doctors, college athletics
coaches, teachers, as well as medical students (the
largest contingent) participate. Admission to the
medical student program is fairly competitive; less
than one in eight applicants are accepted . This
summer, four groups of sixteen medical students
were invited. In each session, eight students participated in the inpatient program while the other eight
were involved with the family program. Schools
from all over the United States and Canada were
represented.
Our days began at 6 am with a short bus ride
from the Howard Johnson's Hotel where all the
medical students stayed free of charge. Although
we were exceedingly well-briefed beforehand, no
one was spared the anxiety of stepping into an unfamiliar family group or onto units inhabited by
twenty strangers
with evere addiction problems.
Would we be accepted or perceived
as intruders?
I
recall watching the
emoti ons on the
face of the first
woman
I
met
change
from
surprise to embarrassment as she
shuffled along the
hall still "coming
down", her hair dishe-veled, and her
mo v ements
unsteady. Oddly,
by the end of the
afternoon this lady
A t Oran ~- responding to tht n<tds o( the
rnrdtcal prokssion is a team approach. And. as a
and I were betram. wr ser our mast imponaru job is to ensurr
ru;~omrr
satiSfaction.
coming friends.
Sperd of response and flexibility. from initial sal<s
She had a quick wit
contact. through order processing. sltippong and
tOtlow-up IS whaJ Oran ~ CliSlORlnS !.......
and a warm smile.
com. to deprnd on.
She also had a long
Oran Russdl IS a lUI-line dislribiior o( medical
diagnostic equipmmt, swgial supplies &
series of purple
Instruments and cbug:s & pbannaa:uti<:;l to
thousands o( h<akh """' prokssionals throughotl
marks
on
the
Ontano.
Tll/1: 10 a Dtwl RziSSd/ trpn:SCIIIOtM• todqy and
medial surfaces of
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she had injected
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heroin. Most of us
187 Hyman 51 .• l.Dndon. Onl3rio (519) 433-9 260
rotJ. FREE H I00-265-7907 F:vr (5t9) 673-5684
in the program
quickly realized
that this was not

Response
1eam
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the time to play junior doctor. We were there to
learn from them, not the reverse, and they knew it.
A typical day began with a thirty minute
meditation walk around the Center and breakfast
w ith the patients . Morning activities involved
exercise (everyone participates, no exceptions),
lectures, and group therapy. Departure to each
activity was preceded by a call to "circle". In circle
we recited the Serenity Prayer ("God grant me the
serenity to accept the things I cannot change .. . "),
joined hands and chanted the unit chant (" orth
Hall, we stand tall, no more drugs or alcohol.. .").
Three lectures each day were designed to provide
the patients with insight into their addiction and
ranged from the pharmacology of abuse, to spirituality, to family dynamics and self-esteem. The
lectures were of a consistently high calibre and were
often extremely inspirational and entertaining. In
addition to these activities medical students attended lectures on the behind-the-scenes workings
of the Center.
Group therapy can be intensely emotional and
personal-this was definitely one of the highlights
of the program for us. While patients occasionally
greeted our presence in "group" with mistrust, most
of us were quic k ly accepted and actually
encouraged to participate.
Activities relate d t o the AA Twelve-Step
program, upon which treatment at Betty Ford is
based, are carried out in the afternoons. The first
five steps take p lace at the Center and the
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remainder are executed after discharge. Aocoholics
Anonymolus meetings, which may also include
graduates from the centre and members of the
community, are held on the campus in the
evenings.
For the medical students, there were more
memorable times waiting each night around the
hotel hot tub as we sat and soaked, reflecting on
the day. Comparing notes, we found that without
exception, every student experienced a bond to the
patients they were in contact with. We also realized
the unfortunately high relapse rate after a single
course of treatment. According to veteran
therapists at the Center, there is no way to predict
an individual's long-term sobriety.
The Betty Ford Center staff, approximatel y
eighty-percent of whom are recovering themselves,
put on an unforgettable training program for us.
We feel that the experience was extremely valuable
to us. The interpersonal skills we refined will assist
us in all areas of medicine.
Addicted and alcoholic persons have a message,
and perhaps a lesson, for those willing to listen.
Q

Applications to attend the Betty Ford summ er
training course may be obtained by writing to :
Betty Ford Centre,
Training Department,
3900 Bob Hope Drive
Mairape, Ca 922702

Car!Pg
For
Canada~s

Health.
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THE POTENTIAL VALUE OF
PSYCHEDELIC DRUGS:
THE
MPTP AND MDMA
STORIES
Jeffrey Poltisky, Meds '94.
INTRODUCTION
allucinogenic agents have a long history of
being prepared to create altered sta tes of
mind. This history may even pre date
ethnologic records of these agents (see article by
Aron Ross in this issue). Ethnologically,
hallucinogens have been prepared from n a tural
sources and used for ceremonia 1, religious, and
medicinal purposes. A recent trend in the use of
mind-altering substances
involves chemical synthesis
of ps y chedelic drugs for
recreational use-the socalled "designer drugs." In
addition to their recreational
use, psychedelic drugs are
also used therapeuticall y
and investigationally. The
synthesis of psychedelic
agents
is
based
on
legitimate pharmaceutical research, and has
resulted in the production of a variety of mind
altering substances, each with an interesting history.
The two major classes of designer drugs are
synthetic phenylethylamines (mescaline analogs)
and synthetic opioid derivatives. This paper
presents a discussion of two psychedelic drugs: 1meth y 1-4-phen y 1-1,2,5,6-tetrah ydropyr i dine
(MPTP}, a derivative of meperidine synthesis, and
-meth y 1-3 ,4-meth y lene-dioxyam phetamine
(MDMA), a mescaline analog. MPTP is used in the
development of animal models designed to further
understand the pathologic basis of Parkinson' s
Disease. MDMA has potential therapeutic value in
the treatment of patients who exhibit psychological
disturbances.

H

MPTP (1 - METHYL-4- PHENYL-1,2,5,6-TETRAHYDRO PYRIDINE)
MPTP, a known neurotoxin, was discovered as a
result of a bizarre detective story. In the late 1970's,
a 23-year-old chemistry graduate student in
Berkeley, California spontaneously developed
severe Parkinsonian-like signs and symptoms that
lasted 18 months . Autopsy revealed selective
degeneration of the substantia nigra, thus
supporting the diagnosis of Parkinsonisml. Further
24

research by scientists from the National Institute of
Mental Health (Bethesda, Maryland) showed that
the subject was a drug addict and had been
synthesizing meperidine analogs for illicit s ale.
Analysis of chemical samples obtained from the
student's basement laboratory revealed MPTP as a
contaminant. Subsequent to this event of sudden
death, investigators identified several young adults
in northern California who presented with virtually
identical clinical signs 2 •3 • The facts that th e se
individuals were also d rug
addicts and that the second
outbreak also occurred in
northern California Led
investigators to suspec t a
toxic contaminant. Indeed,
drug samples analyzed from
an illegal lab ora tory showed
MPTP to be the likely
toxin 2 •3 • These clinical
observations
promp t ed
pharmacologists and clinicians to probe the
physiologic, pharmacological, and toxicological
aspects of the chemical intermediate MPTP.
PHYSIOLOGIC EFFECTS IN HUMANS

In 1983, Langston and coworkers reported on
four drug addicts who had been ingesting the
synthetic heroin MPPP 2 • These addicts had been
producing MPPP in a clandestine basem e nt
laboratory. Each subject presented with signs and
symptoms remarkably similar to Parkinson ' s
Disease (PD); the presentation of these subjects was
thought to be due to contamination of drug samples
with MPTP. In 1985, the same group reported on
seven human cases of known MPTP-toxicity, in
which each patient was diagnosed with clinically
significant signs of the Parkinsonian state3 •
The subjects studied self-administered, by
intravenous injection, MPPP in amounts ranging
from 4.5 grams (g) over four days to 30 g over 20
days. The frequency of administration ranged from
3-10 injections per day3 • Biochemical, haematologic,
urologic, radiologic, and neurologic studies were
non-contributory in all subjects. Each subject
manifested clinical symptoms with acute and
chronic components. The following signs were
associated with the acute component. Intravenous
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administration resulted in a burning sensation in
each subject. Subjects all felt typical heroin-like
euphoria or dreaminess along with illusions,
hallucinations, and blurred vision. Motor
disturbances included sudden distal limb jerkiness
and bradykinesia. Eventually, bradykinesia
predominated and was accompanied by slow,
dysarthric speech and intermittent resting tremor.
Four of the seven subjects reported being "frozen"
by three days post-administration. The chronic
stage of MPTP neurotoxicity developed in days to
weeks and consisted of most of the cardinal signs
and symptoms of PD. These signs and symptoms
included bradykinesia, rigidity, tremor, cogwheeling, micrographia, masked facies, widened
palpebral fissures, glabellar sign, hypophonia,
odynophagia, seborrhea, and diaphoresis 3 •
Combination therapy of carbidopa/levidopa
dramatically improved the extrapyramidal
symptoms of most subjects. Symptoms, however,
returned if therapy was discontinued . Moreover,
increasing doses of carbidopa and levidopa were
necessary to suppress clinical signs3 •
PHARMACOLOGICAL PARAMETERS

After MPTP is administered to primates, it
rapidly disappears from all tissues except the eye•,
and produces no detectable basic, acidic, or neutral
metabolites in organic extracts of biological tissues.
Within one hour, large amounts of the highly watersoluble 1-methyl-4-phenylpyridinium (MPP+) ion is
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detectable in peripheral tissues and in the central
nervous system (C S)4-6. In contrast to the rapid
disappearance of MPTP, MPP+ (half-life, 48-100
hours) is extremely long-lasting in the primate
brain. Further, while MPP+ concentrations begin to
decline in most brain regions and throughout the
body between 24 and 72 hours after administration,
MPP+ levels are actually increasing in the
substantia nigra 7 • Metabolism of MPTP to MPP+
takes place via a two-step oxidation process with
the production of 1-methyl-4-phenyl-2,3dihydropyridinium (MPDP+) ion. Evidence
suggests that this reaction is mediated primarily by
monoamine oxidase (MAO)-Bs- 12 • This ion may be an
important intermediary toward achieving
significant CNS concentrations of MPP+. For
example, some observations suggest that MPP+
does not cross the blood brain barrier (BBB) and
must be injected directly into the C S 13- 15 • This
concept contradicts various animal models
designed to study the effects of MPTP. These studies
employ i. v. injections of MPTP. Perhaps i. v.
injections result in significant CNS concentrations
because MPTP is converted to MPDP+ which first
crosses the BBB and is then converted into MPP+.
NEUROTOXICOLOGIC PARAMETERS

Injection of MPP+ into the striatum, medial
forebrain bundle, or substantia nigra of rats resulted
in marked striatal dopamine (DA) depletion 13- 15 •
MPTP-induced dopamine depletion has also been
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reported in mouse substantia nigra, nucleus
accumbens, and olfactory tubercle 3•16.17 . Although
MPTP has been effective in producing dopamine
depletion, actual neuronal cell loss has proved more
difficult to produce. To date, primates remain the
only animal that develops the major clinical signs of
a full-blown and enduring extrapyramidal
syndrome analogous to that seen in idiopathic PD 18 •
MPTP causes similarl y selective and extensive
destruction of neurons of the substantia nigr a par
compacta (S pc) and the locus coeruleus in primate
brain 19 •
This species variability may exist because of the
fact that whereas MPP+ disappears quickly from
rodent brain, MPP+ is the predominant metabolite
retained in primate brain for long periods. These
differences may relate to inherent differences in
response of cells to MPTP and its metab o lites .
Rodent liver and brain cells metabolize MPTP and
MPP+ quickly; primate cells are much more
sensitive to these toxins 20 •
Other neurochemical changes which occur in
primate brain tissue include reductions in acid
metabolites of dopamine, norepinephrine, and
serotonin in the medulla , pons, midbrain ,
hypothalamus, putamen, caudate, and frontal
cortex21 •

CLINICAL SIGNIFICANCE:
THE LINK BETWEEN MPTP AND PD
Parkinson ' s Disease is a neuropathological
disorder characterized by degenerative changes in
neurons in the S pc and consequential reductions
in striatal DA content22 • In addition to the S pc,
pathologic changes in idiopathic PD also include
the locus coeruleus and the hypothalamus 22 • These
brain regions also contain high densities of binding
sites for MPTP 23; this localization of binding sites
establishes a potential link between MPTP
neurotoxicity and idiopathic PD. Both conditions
present clinically with akinesia, rigidity, and tremor.
Pervading theories regarding causation of PD
include genetic factors, C S aging, and foreign
agents (microorganisms and toxins) . Barbeau and
co-workers have suggested that the pathologic
mechanisms of PD may be associated with
exposure to environmental factors or endogenous
toxins in genetically predisposed individuals
subject to the normal processes of aging20 • One such
potential toxin is MPP+.
The primary clinical relevance of MPTP is based
on the accumulation of MPP+ in the S pc7·24 •
Knowledge of this anatomic selectivity prompted
investigators to utilize MPTP and MPP+ as
substances which could induce clinically significant
Parkinsonian symptoms in animal models . This
26

resea r ch w as expected to expand scienti fic
understanding of the underlying neuropathologic
mechanisms of MPTP-induced Parkinsonism and of
idiopathic PD. Although a number of plausible
theories have arisen to explain these mechanisms,
the pathologic basis of PD or drug-indu c ed
Parkinsonism is still unknown.
One theory which does have credence, however,
relates to S iron stores. The "Iron Hypothesis" is
based on the fact that basal ganglia structures are
rich in iron 25 • In the presence of ferrous iron, MPTP
forms superoxide ions and oxidizes DA 26.v. Thus,
basal ganglia iron stores may contribute to the
mechanism of MPTP neurotoxicity. Iron stores also
appear to play a role in idiopathic PD; autopsied
brain tissue from patients with clinically diagnosed
idiopathic PD revealed elevated concentrations of
S iron 26 • The putative role of iron in MPTPmediated neurotoxicity and in idiopathic PD
provides indirect support for the theory that
pyridine analogues are involved in the underlying
pathology of PD.
As well as being used to explain the pathologic
basis of disease, animal models may also be used to
screen drugs designed to treat disease. Murine and
monkey models of PD have been employed for this
purpose. Tatton and co-workers have utilized a
murine model of MPTP-induced Parkinsonism to
detect the value of drugs which slow progression of
dopaminergic striatal neuronal degeneration 27 •
Research by this group has shown that the MAO
inhibitor deprenyl prevents the death of toxically
damaged neurons. The mechanism of action may
not involve blockade of conversion of MPTP to
MPP+. Another group has found that the MPTP
monkey model is useful for predicting the potential
value of new anti-Parkinson's drugs 28 • Levodopa, a
DA agonist used to treat PD, frequently causes
dyskinesia, the long term side effect of therapy.
These researchers are using an MPTP monkey
model to study the long term effects of potential
anti-Parkinsonian drugs, with the hope that a drug
will be found that does not produce dyskinesias.
MDMA (N-METHYL-3,4-METHYLENEDIO XYAMPHETAMINE)

MDMA is a methoxylated amphetamine base
that was first synthesized in 1912 . MDMA is
derived from materials which contain a
methlenedioxyphenyl ring, such as isosafrole,
safrole, piperonal, and peiperonylactone. The Dstereoisomer of MDMA is quantitatively more
potent at exerting its effects than the L-isomer 29 •
MDMA has many code names, including ecstasy,
XTC, E, Adam, and Eve. This hallucinogen has
been available on the illicit drug market since 1968.
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The drug's popularity grew throughout the 1970's
and 1980's and since the drug enforcement agency
(OEA) placed MOMA on Schedule 1 of the
Controlled Substance Act in 1985, MOMA has
gained even more prominence30 •

Rat brain regions affected by MOMA include the
cerebral cortex, basal ganglia, septal area, thalamus,
epithalamus, hypothalamus, hippocampus, and
midbrain 32• The pharmacologic profile of MDMA at
various CNS receptor and uptake sites is: 5-HT
uptake > alpha2 adrenergic = 5-HT2 = M1
(muscarinic) = H1 (histaminic) > norepinephrine
uptake= M2 = alpha1 adrenergic= beta adrenergic
> OA uptake = 5-HT1 >> OA 02 > DA 0132.
Studies of the effects of MOMA on rat brain shoed
that the dopaminergic and serotonergic systems are
significantly affected by MDMA. MOMA has been
shown to decrease levels of tryptophan hydroxylase
{TPH), serotonin (5-HT), and 5-hydroxy-indole
acetic acid (5-HIAA) in several brain regions 33.34 . As
well, effects on serotonergic system are much more
pronounced and longer lasting than on
dopaminergic neurons 35 • Dopamine appears to be
crucial for MOMA to exert its effects on
serotonergic neurons, since haloperidol blocks the
effects of repeated doses of MDMA. Further,
deinnervation of SN DA neurons with 6-hydroxy
dopamine (6-0HDA) prevented the decrease in
TPH levels in rat neostriatum compared with nontreated brain regions such as the frontal cortex and
hippocampus36 • Finally, both DA and 5-HT uptake
blockers (amfonelic acid and fluoxetine,
respectively) also block MDMA-induced decreases
in TPH levels 37.38.

PSYCHOLOGIC AND PHYSIOLOGIC EFFECTS

Subjects taking MOMA report a sense of
"closeness" in the first few hours after ingestion 31 •
Various physiologic effects also occur and include
tachycardia , dry mouth, tremor, palpitations,
diaphore is, parasthesias, trismus, and bruxism.
Whereas many people report an increased
alertness, many people also report a decreased
ability to concentrate. A minority of subjects also
report visual, but not auditory, hallucinations.
These hallucinations tended to occur in the
peripheral and not the central visual field 31 •
Twenty four hours after ingestion, subjects
tended to feel drowsy. This drowsiness is likely
associated with the insomnia of the previous 24
hours. Muscle aches, fatigue, depression, difficulty
concentrating, and headache were also experienced.
The worst subjective sensations however, were a
sense of anxiety, worry, fear, and irritability 24hours post-ingestion 3 1• About one half of MOMA
users report that the positive effects of the drug
diminished with repeated administration, whereas
the negative effects tended to become more
profound.

Compliments of·

~~~'
MERCK FROSST CANADA INC.
Wh e r e to day:\" r esearch is tomo rrows the r apy

Compliments
~

of

~~

Kabi Pharmacia Canada Inc.
500 Morgan Boulevard
Baie d'Urfe, Quebec .
H9X 3Vl
U.W. O. Medical Journal 62 (l) 1 9 9 2 - - - - - - - - - - - - - - - - - - - - - - - - -

27

Feature

Section

MDMA TOXICITY

CLINICAL USE OF MDMA

MDMA toxicity has been studied on a variety of
animal models. For example, doses which cause
death in 50% of subjects tested (LD50) range from
32 mg/kg in rat, to 14 mg/kg in dogs, and 22
mg/kg in monkey39. Lethal doses in man may only
be inferred from various sources of literature, and
the values vary. Levels near 1 J.Lg/ml have been
associated with fatalities40, whereas levels as high
as 7 J.Lg/ ml have no~ •
Therapeutic or recreational uptake of MDMA
usually involves oral doses in the range of 75-100
mg. At this level, a variety of side effects may occur
which include tachycardia, tremor, facial muscle
contracture, diaphoresis, nausea, vomiting, and
bruxism. Disturbances become more severe as
dosage is increased. Impaired cognitive, sensory,
and motor skills have also been observed30.J1•
Brain regions that suffer the greatest extent of
MDMA-induced neurotoxicity also exhibit dramatic
reductions in 5-HT uptake sites. For example,
cortical regions that showed the most extensive
destruction by autoradiographic analysis included
the prefrontal, anterior cingulate, entorhinal, and
parietal cortical regions32• These changes occurred as
early as 18 hours after a four-day treatment regimen
of 20 mg/kg MDMA (b.i.d.). The caudate-putamen
regions, thalamus, and hippocampus also showed
early degenerative changes 32 • In the midbrain,
regions with 5-HT projections (such as the terminals
and axons of the SN) were more dramatically
disturbed than regions with 5-HT uptake sites (i.e.
perikarya) such as the raphe nucleus, central gray,
ventral tegmental area, and pontine reticular
formation 32 •
The severity and extent of MDMA-induced
lesions depend highly on the dose and frequency of
administration. Neurotoxic effects may persist up to
one year before structural recovery may occur;
functional impairment can be permanent.
Human deaths associated with MDMA may be
direct or indirect. Direct deaths due to high doses
may be due to overwhelming neurologic
involvement, with a special risk for people with
underlying cardiovascular disease. Indirect deaths,
which seem to be more common, are likely due to the
effects of cognitive, sensory, and motor impairment
induced by MDMA-for example, a motor vehicle
accident. As well, many people who have died with
significant blood levels of MDMA have also had
trace or significant blood levels of other drugs such
as alcohol, cocaine, lysergic acid diethylamide (LSD),
dextromethorphan, acetaminophen, and others.
Thus, attributing death to MDMA is difficult not
only on the basis of the effect of the drug itself, but
also on the predisposition of the use~.

MDMA was first used psychotherapeutically in
the late 1970 ' s (before the drug was place d in
Schedule 1 by the DEA) for patients who exhibited
addictive behaviors. MDMA appeared to have the
ability to assist the patient in surrendering his w ill
to a "Higher Power" for personal guidance toward
ultimate achievement of self-control. This attitude is
thought to be critical in aiding the patient to gain
release from previously destructive addictive
behaviors, relations, and beliefs . One other
important aspect in the therapeutic use of MDMA
(and other psychedelic drugs) is the patient's
understanding that the therapist has undergone
MDMA training sessions and is capable of
appreciating the subjective effects of the dru~.
Patients who are acceptable candidates for
MDMA psychotherapy should fulfill the following
criteria: they should not have peripheral vascular
or cardiovascular disease, they should not be on
psychotropic medication, they should not h a ve
metabolic disturbances or liver disease, and th ey
should not be pregnant~3 • Further, such patients
should be relatively well-adjusted people with a
willingness to solve their problems.
The patient should also be instructed of all
potential benefits and risks of the drug so that the
patient may give informed consent for the session.
The benefits include enhanced communication,
introspection, and elevated mood . The
physiological risks are associated with the
sympathomimetic side effects of MDMA (bruxism,
tachycardia, nausea, vomiting, hypertension) and
with the potential5-HT depletion and neurotoxicity
based on animal studies. The psychological side
effects relate to the breakdown of the patient's
defense mechanisms; the pain of incompletely
reconciled grief or previous traumatic experiences
may be felt both psychologically and somatically.
Symptoms that may occur include psychologic
depression and anxiety as well as headaches and
dyspnea 43 • Side effects are not known to last beyond
one to two days, whereas the duration of potential
benefit from a successful session may be
immeasurable.
The entire therapeutic session may last may
hours. After taking the drug, patients initially spend
some time in isolation either in silence, meditation,
or prayer waiting for the drug to take effect.
Patients may continue to spend time alone in
introspection once the drug begins to exert its
effects. Once the patient feels confident with the
individual issues and various physical signs, the
patient is encouraged to confront these issues with
the therapist. An additional 50 mg dose of MDMA
may be offered to extend the effects of the drug.

1
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Once the session is over and the drug effects begin
to wear off, the patient may want to discuss the
entire episode in eamest with the therapist 43 •
Greer and Tolbert found that about 90 % of
patients had positive and beneficial experiences
with MDMA 44 • These researchers concluded, based
on various clinical encounters, that MDMA serves
to reduce emotional stress and fear associated with
perceived threats to one's psychological integrity«.
Exactly how MDMA achieves this loss of fear is
unknown. Nonetheless, patients gain access to
unresolved conflicts from childhood and other past
relations and feel as though they have gained a
broader, more complete understanding of
themselves and their relations with others44 •
Currently, psychotherapeutic applications of
MDMA is legal only in Switzerland. Recent reports,
however, suggest that the Food and Drug
Administration (FDA) may lift the existing ban on
research employing LSD and MDMA 45 • The Swiss
group of Widmer and colleagues use MDMA to
study human consciousness47 • Treatment of selected
patients consists of two to four treatment sessions
per year with MDMA or other psychoactive
substances. Widmer's group have not observed any
addictions MDMA. Further, addictions to alcohol,
medical drugs, heroin, and other agents have been
greatly
reduced
by
MDMA-supported
psychotherapy46. No evidence has accumulated to
substantiate suspected CNS toxicity due to MDMA
in the therapeutic dose range 46 •
The current restriction on the therapeutic use of
psychoactive substances suggests that these agents
have not received the necessary scientific
credentials to make this type of therapy acceptable.
The lack of scientific support, coupled with negative
social attitudes toward the use of psychoactive
agents for medical treatment, make the likelihood of
government-supported research a distant
possibility. Only knowledge (gained from studies
similar to those by Greer and Tolbert, and by
Widmer et al.) may change this trend from rejection
to acceptance.
CONCLUSIO N

Psychedelic drugs continue to be preferred
agents among drug users to create altered states of
mind. MPTP and MDMA are only two examples of
a number of chemical compounds that have arisen
as a result of psychedelic drug synthesis. Clearly,
uncontrolled use of these agents can produce
profound toxic effects in humans with disastrous
results. In a controlled environment, however, each
agent has a potential scientific benefit. Further
research with MPTP may assist scientists not only to
elucidate the underlying mechanisms of PD, but to

Section

develop improved treatment modalities for this
disease as well. Further, controlled therapeutic trials
with MDMA may prove this agent to be a useful
adjunct in the treatment of addictive disorders and
psychological disturbances.
The current surge in interest in MPIP, MDMA,
and other such chemicals for the treatment and
study of neurodegenerative, addictive, and
psychological disorders suggests that hallucinogens
and their byproducts will play an important role in
the progression of scientific knowledge.
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BUFOTENINE AND THE 11 TOAD
LICK I NG" PHENOMENON:
HISTORICAL PERSPECTIVES AND
CURRENT T RENDS
Aron D. Ross

INTRODUCTION
The ritual use of bufotenine as a hallucinogenic
drug has long been practiced within some South
American tribal cultures, but until recently, its use
among North American drug users was virtually
unknown. In the last few years, bufotenine has
become the subject of media controversy when
street-drug users were reported to have ingested
bufotenine-containing toad v enom for
its alleged hallucinogenic effects; the
media dubbed this practice "toadlicking". These reports have revived
interest in the hallucinogenic properties
of bufotenine, but to date v ery few
thorough accounts of the current toad
licking phenomenon ha v e been
published. Although this curious
practice is not likely to become a
widespread drug abuse problem, it
does merit a detailed examination.

HISTORICAL PERSPECTIVES AND
ETHNOPHARMACOLOGY
Bufotenine is a hallucinogenic
alkaloid found in several species of
toads, plants and fungi. Bufotenine is the principal
plant alkaloid from the seeds of Anadenanthera (Fig.
1), a genus of leguminous trees consisting of the two
species A. peregrina and A. colubrina . Tribal
groups of South America use these species to
prepare a hallucinogenic snuff powder which they
consume. The earliest record of snuff prepared from
A. peregrina is likely from 1496, when Europeans
observed Taino Indians of Hispaniola selfadministering the snuff by nasal insuffla t ion
through a long bamboo tube. This snu ff was
reported to prod uce a rapid hallucinogenic effect
and was primarily used in magicoreligious
ceremonies 19 • Similar snuffs, called yopo, cohoba or
ABOUT THE AUTHOR:
Aron Ross is currently enrolled in a PhD program in Pharmacology at
the University of Toronto. Mr Ross has also obtained B.Sc and M.Sc degrees
in Pharmacology (University of Toronto).

parica, made from the ground seeds of A. peregrina,
were (and may still be) used by various tribal groups
nativ e to British Guyana, Brazil, and the Upper
Orinoco Valley region of Venezuela and Colombia.
The closely related species A. colubrina is found in
the snuffs known as vilca or hulica in Southern Peru
and Bolivia, and cebil in Northern Argentina. Each
Indian tribe prepares the snuff in a slightly different
manner but generally the seeds are toasted and
ground into a powder which is
mixed with lime from crushed
snail shells or ash from the
bark of certain trees. The
powder is then sniffed through
a tube made of wood or bird
bone2. The alkaline plant ash
and lime are thought to act not
only as binding agents, but to
facilitate the diffusion of
alk aloids through the nasal
mucosa as well. A typical 5
gram dose of yopo snuff is
taken up to three times a day
and
produces
a
rapid
intoxication, of 15-120 minutes
duration characterized b y
initial stimulation, excitement,
Figure# 1
and hallucinations followed by
a hypnotic or unconscious state. As well as
bufotenine, Anadenanthera seeds also contain lesser
amounts of two chemically related hallucinogenic
alkaloids, dimethyl tryptamine (DMT) and 5methoxy-DMT, both of which may contribute to the
hallucinogenic properties of Anadenanthera snuffs.
In addtion to plant species, bufotenine is also
contained in the toxic secretions of the cane toad
(Bufo marinus) and the Colorado River or Sonoran
desert toad (Bufo alvarius). The cane toad is found
in South and Central America, the Sou thern United
States, Puerto Rico, Hawaii, and Australia, In
response to provocative stimuli, the toad secretes a
milky white venom from the parotid gland s. This
venom serves as a very effective natural defense
against pred ators since, in addition to bufotenine,
the toad venom also contains p otentially lethal
quantities of digitalis-like cardiac glycosides 16 •
Archaeological findings of large qu antities of Bufo
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skeletal remains from the ancient Olmec ceremonial
site of San Lorenzo, Veracruz (1200-900 B.C.)
suggest that the Olmec had knowledge of the
properties of cane toad venom and may have used
it as a "fortifier" in fermented ritual beverages 19 •
Preparations of cane toad venom are still in use by a
few indigenous tribal healers in Veracruz, Mexico,
who use techniques passed down for generations to
process and detoxify the venom, which is rolled into
pills for later uses, for example, as an aphrodisiaCS.
Along with plants and toads, bufotenine has
been isolated from certain species of fungi. Small
amounts of bufotenine have been found in
hallucinogenic mushrooms of the genus Amanita 1 •
The psychotropic properties of that sp e cies,
however, are more likely due to the presence of the
two principal alkaloids ibotenic acid and
muscimoJ1 8 • Interestingly, literary references have
often associated mushrooms with toads, as for
example the use of the word "toadstool" to describe
certain toxic mushrooms. Similar chemical relations
of certain hallucinogenic toad and mushroom
species may have been known long before these
associations could be validated scientifically.
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PHARMACOLOGY O F BUFO TENINE

Bufotenine, also known as 5-hydroxy-N,Ndimethyltryptamine (5-0H-DMT) and dimethyl
serotonin, is a serotonin homologue whi ch is
closely related structurally to the hallucinogenic
alkaloids DMT and 5-methoxy-DMT (Fig. 2).
Bufotenine was first synthesized in the 1930's.
Over two decades later, in 1956, the
pharmacological effects of bufotenine in humans
were first reported 4 • In a study by Faber and
Hawkins, intravenous (IV) doses of bufotenine (416mg) were administered to four inmates at the
Ohio State Penitentiary. The subjects experienced
dose-dependent psychological effects including
vivid colour hallucinations, mental confusion, and
feelings of euphoria and depersonalization. The
physiologic effects noted were mydriasis,
nystagmus, parasthesias, burning mouth, chest
pain and dyspnea, nausea, vomiting,and purpling
of the face and neck. The purple colour was
described as "the approximate hue of an eggplant"

32

and was thought to be due to serotonin-induced
bronchiolar constriction and consequent
hypoxemia. One subject's subjective experience
with the drug was described in the following w ay:
"He saw red spots passing before his eyes and red
purple spots on the floor, and the floor seemed very
close to his face. Within two minutes the visual
phenomena were gone but they were replaced by a
yellow haze". The psychologic effects, which are
reminiscent of side effects caused by LSD and
mescaline, developed rapidly and disappeared
completely within 7-60 minutes , in a dosedependent fashion. A subsequent study reported
similar effects from intramuscular (IM) injections of
bufotenine at doses of 10-15 mg, but no observable
effect was noted when bufotenine was gi v en
intranasally at a dose of 14 mg or orally at doses of
up to 100 mg. The inefficiency of oral dosing is
likely due to the extensive first-pass metabolism by
monoamine oxidase3 • Pharmacokinetic studies have
found that IV bufotenine is very rapidly absorbed
from the blood and excreted in the urine,
predominantly (70%) in the form of the metabolite
5-HIAA. Roughly 4% can be recovered from the
urine in the unchanged form 11 • The toxicity of
bufotenine in humans is not well known. Certain
toxic responses, however, have been observed. An
intra-muscular (IM) injection of 40 mg of
bufotenine produced tachycardia, auricular
fibrillations and extreme cyanosis in one patienflO
and resulted in the development of car d iac
arrhythmias of the nature of multiple ectopic beats
from supraventricular foci, at IV doses of 10-15
mg 3 • The pharmacological and toxicol o gic
mechanisms underlying the behavioral effect of
bufotenine have not yet been extensively studied,
but there is evidence to suggest that its action as a
partial agonist at serotonergic 5-HT2 receptors is
involved 10•
CURRENT TRENDS: "TOAD LICKIN G "

For the past several years reports have
circulated of a new trend in the use of bufotenine as
a street drug - in the form of "toad licking" - the
practice of ingesting the hallucinogenic secretions
of the cane toad. This bizarre new practice caused
something of a media sensation; exaggerated
accounts of toad licking appeared in news reports
throughout North America where toad licking was
often referred to as the "latest fad" . Media attention
to the toad licking phenomenon seems to have
begun shortly after the release of a critically
acclaimed 1987 comic documentary Cane Toads by
Australian film-maker Mark Lewis. The film dealt
with the colourful history of the cane toad in

Australia and alluded to the possibilities of
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ingesting toad venom for its hallucinogenic effect.
Both the film and toad-licking received major press
coverage in newspapers and magazines throughout
orth America, with articles appearing in
ewsweek 24, The ew York Times 9 , Scientific
American 8 , Smithsonian 13 and Medical Pose 1, and
various local newspapers. Doubt exists as to
whether toad licking was ever practiced among
North American drug users prior to the media
reports that drew attention to the hallucinogenic
possibilities of toad venom. Contrary to what the
sheer volume of reports would indicate, toad
licking is still a rare occurrence. At least four
incidents of deliberate toad venom ingestion have
been documented, all of which resulted in
hospitalization. In New Mexico, two teenagers
ingested cane toad venom after reading news
reports of the "fad", and had to be hospitalized 8 •
Further, in Australia, deaths have been reported as
a result of ingesting cane toad eggs 13 and after
drinking tea brewed from cane toad venom 23 •
Media publicity was again an instigating factor
when two Toronto men, aged 28 and 31, ingested
cane toad secretions within a few days after
watching a CBC-TV screening of Lewis' film Cane
Toads6.14· 15 • One of the two men had to be treated in
the intensive care unit at North York General
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Hospital for seizures. One of the most thoroughly
documented cases of intentional cane toad venom
ingestion was reported by a pediatrician who
treated a 10 year old boy admitted to the
emergency ward at a Florida hospitaJ1 7 • Upon
admission, the boy was experiencing acute
episodes of incoherence and complained of severe
headaches and hallucinations. Electrocardiographic
findings revealed secondary atrioventricular block
(type I). No other clinical findings were sigrtificant.
The boy was given i.v. fluids and monitored
overnight. The next day both his behavior and
electrocardiogram had returned to normal and he
later admitted that he and his friends had been
licking cane toads for the purpose of "acting
crazy".
The most prominent clinical features of cane
toad poisoning consist of profound drooling,
seizure activity, arrhythmias, and cyanosis.
Treatment for bufotenine intoxication is based upon
supportive and symptomatic measures.
Recommended drug therapy can include activated
charcoal, hydrocortisone sodium succinate for
respiratory complications, phenobarbital to control
seizure activity, phenoxybenzamine (an a-receptor
blocker) to relieve hypertension, and propranolol (a
B-blocker) to reverse cardiac arrhythmiasl2,7.
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LEGAL STATUS

Bufotenine is not available by prescription
anywhere in the world nor does there appear to be
an illicit market for the synthesized drug. In the
United States bufotenine is covered under Schedule
I of the Controlled Substances Act (the same
schedule that covers highly addictive drugs such as
cocaine and heroin) since there is the potential for
abuse and no known medical uses for bufotenine.
Rumours about a bill to ban toad licking in Georgia
were later reported to be false 23, but other sources
mention that such a bill is under consideration in
South Carolina 17 • The government of Queensland,
Australia has restricted the use of Bufo secretions by
classifying them as dangerous substances under its
Drug Misuse Act 22 • In Canada, toad-licking is not
illegal, according to a quote from a Toronto police
constable, and cane toads are sold legally at several
pet stores 15•

continued media attention to the hallucinogenic
possibilities of these agents, further incidents
involving cane toads or other bufotenine containing
substances may be anticipated. Considering the
likelihood of serious injury as a consequence of toad
venom ingestion, medical clinicians should be
aware of this phenomenon and attempt to monitor
the emergence of this drug abuse trend in the
future.
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PSYCHEDELIC DRUG
UPDATE
THE HOASCA PROJECT:
PROPOSAL FOR A BIOMEDICAL
INVESTIGATION O F AYAHUASCA
Dennis J. McKenna, Ph.D.
yahuasca is a Quechua term meaning "vine
of the souls," and is one of the numerous
indigenous names for the hallucinogenic
drink prepared from a combination of two
Amazonian plants, Banisteriopsis caapi, and
Psychotria viridis. In Amazonian Peru and parts of
Colombia and Ecuador, the drink is known as
ayahuasca; in other parts of the Amazon, it is
known as yage, natema, or pilde; in Brazil, it is
known as hoasca, or sometimes simply "the tea." In
whatever cultural context it is found, and by
whatever name, ayahuasca plays a pivotal role both
in the spiritual life of the populations that use it,
and in local ethnomedical practices. The drink is
regarded as both a sacrament, and a medicine. For
the shamans familiar with its properties, it is both a
diagnostic aid and a respected teacher; for the patients who seek the healing the shamans can offer, it
is the ideal holistic medicine, providing the means
to cleanse and heal both the mind and the body.
From the perspective of modern psychopharmacology, practically nothing is known of
how it actually affects the human mind/body.
Recently, a unique opportunity has become
available to carry out a biomedical investigation of
the immediate and long-term effects of ayahuasca in
human users. This opportunity has resulted from
recent friendships established by the author with
members of a Brazilian organization, the Unao do
Vegetal (UDV) which is essentially a syncretic
religious movement in which the collective,
periodic ingestion of hoasca tea is the central
ceremony and sacrament. Unlike the more
traditional use of ayahuasca in the context of
mestizo or aboriginal shamanism, the use of hoasca
tea within the UDV is strictly regarded as a
religious or spiritual practice (as opposed to a
curing or medical practice). Moreover, many of the
younger adherents to the UDV "cult" tend to be
well-educated urban professionals. Some of the
members are Western-trained physicians,
psychiatrists, or o ther h ealth professionals who
frequently possess a solid training in medical

A

Sect i o n

RESEARCH

disciplines and a healthy scientific curiosity about
the physical and psychological effects of hoasca tea.
They understand as much as anyone does about the
active alkaloids found in hoasca tea, and about its
putative mechanism of action. Many of these
individuals would like to learn all that can be
learned about how it works, but at the same time
they maintain a sense of reverence regarding their
sacrament; they consider that an effort to understand hoasca using the tools and paradigms of
science is not a sacrilege if it is pursued as part of a
sincere effort to increase our know ledge of this
remarkable medicine.
This enlightened attitude establishes an intellectual climate in which a pharmacological and psychological investigation of hoasca could be carried
out if the required resources were available. While
attending a conference on the biomedical aspects of
hoasca which was hosted by the UDV in Sao Paulo
in June, 1991, I made a proposal for a biomedical
investigation of the human pharmacology of hoasca
to some of the leaders of the UDV. The response
was more than receptive, it was enthusiastic. Since
this conference, we have remained in frequent
contact, and have continued to work together on
developing a proposal setting forth the objectives

These articltes were reprinted with the kind permission of Rick Doh/in,
president of MAPS. (See page 38.)
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and methodologies for a pilot study on the action of
hoasca in humans.
As currently conceived, a number of parameters
related to the psychophysiological effects of hoasca
will be investigated, among them the following:
Composition of hoasca teas. The UDV recognizes several kinds of hoasca, which differ in their
modes of preparation and in their effects. The
composition and amount of active alkaloids in these
various types of tea will be analyzed and compared.
Acute pharmacokinetics of hoasca. Pharmacokinetics is the study of the absorption, metabolism,
and excretion of drugs. The phar-macokinetics of
the major alkaloids of hoasca (harmine and DMT)
will be determined in blood samples taken from
volunteers using a technique known as gas
chromatography /mass spectrometry (GC/MS).
Acute/long-term effects of hoasca on serotonergic functions. Hoasca, like other hal-lucinogens,
is known to interact primarily with receptors for the
neurotransmitter
serotonin
(5-HT,
5hydroxytryptamine). The effects of hoasca on
serotonergic functions can be determined in blood
and plasma samples by analyzing various parameters, such as the levels of hormones known to be
modulated by the serotonin system (e.g. prolactin,
ACTH, beta-endorphin) . In addition, blood
platelets contain many of the same serotonin
receptors that are found in the brain, and
psychopharmacologists have long used platelet receptor binding assays as a peripheral marker for
changes presumably occurring in the central nervous system. We propose to use platelets to monitor
the effects of hoasca on certain serotonin receptor
subtypes, and also to measure peripheral
monoamine oxidase (MAO) inhibition. These parameters will be measured in volunteers drawn
from the members of the UDV before and after the
ingestion of known doses of hoasca tea.
In addition, a parallel study will investigate the
possible long-term effects of hoasca by examining
these parameters in a group of older maestres members of the UDV who have taken hoasca
regularly for much of their adult lives.This group of
maestres will be compared with a set of age-matched
control volunteers who have not taken hoasca.
These are the primary objectives of the initial
study. Additional parameters may also be measured, such as the effect of hoasca on immune
functions, or its effect on cognitive function as
measured by psychological and cognitive assessment procedures.

IBOGAINE

UPDATE
by Bob Sisko

ast year, the Medications Development
Division (MOD) of the National Institute on
Drug Abuse (NIDA) began a research
initiative to evaluate the use of ibogaine as an antiaddiction agent. Since than, numerous articles have
appeared in scientific journals, both in the US and
abroad, which show promising results.
Spearheading the research efforts are the
Pharmacology and Toxicology Department of
Albany Medical collefe, headed by Dr. Stanley D.
Glick. His department published no fewer than six
papers in little over a year. Other New york
research institutions evaluating ibogaine include the
Nathan S. Kline Institute for Psychiatric Research, a
facility of the New York State Office of Mental
Health affiliated with NYU Medical Center, and the
City University of New York Medical School.
Claims that ibogaine is effective as atreatment
for both cocaine and opiate narcotics were at first
widely viewed with skepticism. Cocaine is, after
all, a stimulant while opiate narcotics have an
oposite effect, that of sedating the user. What they
do share in common, however, is that use of either
substance increases dopaminergic (DA) activity in
the brain's mesolimbic system, and/or mesocortical
pathways. This triggers the reward mechanism,
which is associated with the reinforcing effects of

L

[Editor's note: At the time this article was
reprinted, the required $50 000 to commence
research was already acquired. ]
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drugs of abuse. Researchers thus began looking at
the relationship of ibogaine to the DA system.
In early 1991, Dr. Broderick of CUNY Medical
School submitted an abstract to the College on
Problems of Drug Dependence (CPDD), The African
Alkaloid, Ibogaine, Alters Cocaine-Induced
Accumbens Dopamine Neurotransmission: In Vivo
Voltametric Studies in the Conscious Brain. She
reported that ibogaine reduced cocaine induced DA
increases, but without complete depletion, and
observed, "These data have clinical implications
because pharmacotherapeutic medications which
decrease DA neurotansmission
without a complete
DA block could
dirdumvent
the
reported anhedonia
often associated
with some cocaine
treatment modalities." Her final
report, presented at
Ibogaine
the CPDD' s 53rd
annual scientific
meeting, concludes, "Thus, ibogaine's effects are
consistent with current views regarding rational
strategies for cocaine treatment." 1
At the same time, researchers at the Division of
eurochemistry at the Nathan Kline Institute in
Orangeburg, NY were examining the relationship
between ibogaine and cocaine in mice. Henry
Sershen, et,al., reported this year tha' Ibogaine
Antagonizes
Cocaine-Induced
Locomotor
Stimulation in Mice 2 • "The results," he states,
"suggest that ibogaine may have induced a selective
change in the dopaminergic system that results in a
decrease in responsiveness to cocaine that persisted
for at least one week." He further concluded that
" The above results are not in conflict with the
proposed uses of ibogaine in the treatment of
cocaine abuse, since increased dopamine
neurotransmission has been shown to be associated
with the locomotor-stimulant and reinforcing effects
of cocaine. Attenuation of the e effects by ibogaine
could possibly reduce the craving for cocaine."
Additional work involving ibogaine and cocaine
was accomplished by m.R. Dzolic, of Erasmus
University in Rotterdam. An abstract submitted to
the CPDD, Effects of Ibogaine on Cocaine SelfAdministration in Rats, showed promising results,
and compared favorably to uncontrolled clinical
observations. "All this is encouraging," said Dzolic,
"s ince it supports the idea that ibogaine is a
potential long lasting interrupter of both cocaine
and morphine dependency."
In June, 1992, Dzolic made and oral presentation
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to the CPDD at the 54th annual scientific meeting in
Keystone, Colorado. The significance of his
findings are twofold. Firstly, heretofore the
interruption of cocaine self-administration with a
non-toxic substance was unheard of. In a number of
widely-reported studies, animals, when given the
ability to self-administer cocaine did so
continuously, ignoring food, water, and sex until
they died. Secondly, Dzolic's findings are consistent
with those of S.D. Glick, et.al., Effects and
Aftereffects of Ibogaine on Morphine SelfAdministration in Rats. 3
Glick found that not only would
ibogaine interrupt morphine selfadministration, but that it continued to do
so long after the ibogaine was eliminated
from the body. Citing two US patents
(4,499,096; 4,587,243) which describe the
potential effecacy of ibogaine in treating
opeate and cocaine addiction, Glick
concludes, "Though far from addressing the
full extent of the claims presented in the
patents, the results of this study suggest that
such claims should be taken seriously, and
that further investigation is warranted."
In a study entitled, Interactions between
Ibogaine, a Potential Anti-Addictive Agent, and
Morphine: An In Vivo Microdialysis Study• I.M.
Maisonneuve et.al. found that "It appears that
ibogaine affects brain DA systems for a period of
time that exceeds its elimination from the body, and
during this time, alters the responses of these
systems to morphine. By preventing the increase in
dopaminergic transmission induced by morphine in
the nucleus accumbens, ibogaine may decrease the
reinforcing efficacy of morphine. Thus, although a
definitive mechanism underlying the claims
regarding ibogaine's therapeutic effects cannot be
specified yet, the results of the preesnt study
indicate
that such
mechanissms
merit
investigation."
Maisonneuve and Glick published two other
papers addressing the dopamine question ,
Interactions between Ibogaine and Cocaine in Rats:
An In Vivo Microdialysis and Motor Behavio~; and
Acute and Prolonged Effects of Ibogaine on Brain
Dopamine Metabolism and Morphine-Induced
Locomotor Activity'.
Glick then turned his attention to another claim;
the claim that ibogaine will suppress the multiple
symptoms of narcotic withdrawal. The claim that
ibogaine attenuated many, but not all, symptoms of
withdrawal was first reported by Djolic et.al., Effect
of Ibogaine on Naloxone-Precipitated Withdrawal of
Chronic Morphine Dependent Rats 7 Two years later,
Aceto, Bowman and Harris at the Medical College of
Virginia reported that ibogaine suppressed
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withdrawal signs in morphine dependent monkeys8•
A controversy was created when Sharpe and Jaffe
refuted those findings, stating that ibogaine failed to
reduce the majority of withdrawal in mor phine
d e pend e nt r a ts . Howe v er, Sharpe and Jaffe
conceded tha t such discrepancies were possibly the
result of methodological d ifferences . " Despite all
these differences," observed Glick, "some aspect of
the opiate withdrawal symptom was ameliora ted in
all three studies."
G lic k prepared a s tudy to re-exami n e the
possibility that ibogaine might attenuate morphine
withdrawal. His res ults indica te that ibo gaine
s ignifi cantl y decrea sed the intens ity o f many
wi thdrawal signs 9 • "Exactly how ibogaine might
attenuate opiate witdrawal is, at this point, op en to
conjecture, " Glick s tate s . "Regardless o f the
explanation," he concludes, " the present results
indicate that the potential usefulness of ibogaine in
treating acute manifestations of opioid depen dence
should be further investigated."
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THE CARDIOVASCULAR AND
NEUROLOGICAL EFFECTS OF
COCAINE TOXICITY
Anne Silas, Meds 94 & Rocco Gerace, M.D.

ABSTRACT
he widespread use of cocaine has led to an increase in Emergency Department admissions for
treatment of the acute toxic effects of this drug. Recently, an increase in fatalities has been ascribed
to its cardiovascular and neurologic complications 1 • These include acute myocardial injury,
arrhythmias, stroke, seizure, and death2 • Recognition of the cocaine abuser's presentation in the ED, and
knowledge of the various applicable treatments, may reduce mortality and morbidity associated with
cocaine intoxication.

T

INTRODUCTION

PHARMACOKINETICS

Cocaine is a naturally occurring alkaloid of the
Coca plant Erythoxylun coca which is found
throughout the Andes mountains. The use of
cocaine dates back at least 5000 years among the
Incas3 • However in Europe, cocaine did not become
popular until the 1860s when the active ingredient
benzoy ' methylecgonine hydrochloride, was
isolated 4 • Prior to this time, the loss of potency
during transport greatly suppressed the popularity
of the coca plant.
In the past decade, the widespread use of
cocaine has led to an increase in emergency
department admissions for treatment of its acute
toxic effectsl. These effects include agitated
delirium, seizure and stroke2, myocardial ischemia
and infarction5.6, as well as tachyarrhythmias and
myocarditis7 • Episodes of silent myocardial ischemia
have also been noted during the first weeks of
cocaine withdrawal8 •
Although the relationship between cocaine
toxicity and We-threatening cardiac events has been
recognized historically as tempora 16, documentation
of cocaine-induced coronary vasoconstriction has
suggested this relationship to be causa 17 • Several
mechanisms, however, have been proposed to
explain cardiovascular complications subsequent to
cocaine intoxication. These include, in addition to
coronary artery spasm, focal coronary
vasoconstriction9, thrombus formation and platelet
aggregation 10 , direct myocardial toxicity 11 , and
increased myocardial oxygen demand 7 •

An understanding of the pharmacologic and
toxicologic characteristics of cocaine is helpful in
understanding clinical toxicity.
There are a variety of forms of cocaine that
allow self administration . For example, cocaine
hydrochloride, a white crystalline powder, is highly
water soluble and administered intravenously or by
nasal insufflation. Cocaine hydrochloride may be
converted to the free-base form by dissolving the
powder in an alkaline solution, using a solvent
such as ether to extract the cocaine, and finally,
evaporating the solvent. Crack is a form of freebase made using baking soda and water4 • The freebase form of cocaine HCl vaporizes at temperatures
greater than 98C without being destroyed, thereby
allowing it to be smoked. Clinical effects associated
with rapid absorption and ease of administration of
free-base form was led to the popularity of
smokable crack cocaine.
The pharmacokinetics of cocaine vary with the
mode of administration of the drug . Cocaine is
absorbed from various sites in the body including
mucous membranes and the gastrointestinal tract.
Following intranasal administration, the drug
begins to exert its effects in about twenty minutes.
The drug's half life may be several hours due to
continued absorption. Smoking cocaine results in
almost immediate pulmonary absorption and
rapidly increasing blood concentration levels.
Cocaine is rapidly and extensively metabolized by
plasma and liver cholinesterases to the water
soluble metabolites ecgonine methyl ester and
benzoylecgonine'0 •

ABOUT THE AUTHOR:
Dr. R. Gerace i a Professor in the Department of Medicine at The
University of Western Ontario and Chairman of the Division of
Emergency Medicine.
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PHARMACOLO GY

CARDIO TO XIC EFFECTS O F CO CAINE

Once cocaine is absorbed, it produces its
effects through local membrane stabilizing and
sympathomimetic actions 10 • The primary target
sites for the effects of cocaine include
cardiovascular and neural tissues 12 • Initially, on
the basis of central dopaminergic stimulation,
cocaine produces euphoria and excitement, as well
as an increase in heart rate and arterial blood
pressure and in severe cases, arrhythmias and/ or
coma. This intense stimulation may be followed
by anxiety, paranoia, and depression of
respiration.
Cocaine has sympathomimetic as well as
anaesthetic properties. By inhibiting sodium
conductance, cocaine inhibits nerve impulse
conduction. Cocaine also produces increased
peripheral catecholamine levels by preventing
presynaptic reuptake of neurotransmitters 12 •
Cocaine's ability to directly stimulate central
vasomotor centres compounds this drug's
potential to create intense sympathetic
stimulation. Small vessel vasoconstriction,
increased vascular resistance, and increased
cardiac output are among the drug's pathologic
cardiovascular effects 13 •

Cocaine's cardiotoxic effects can result from all
modes of administration of the drug6. Further,
underlying heart disease is not a requisite for
cocaine cardiotoxicity 19 • Stimulation of the central
vasomotor centres and rising levels of peripheral
catecholamines produce hypertension and
tachycardia, as well as an initial increase in blood
pressure. The drug's direct toxic effects on the
myocardium may subsequently produce a fall in
blood pressure. The sudden increase in myocardial
oxygen demand, produced by an elevated heart rate
and increased systemic arterial pressure, coupled
with vasoconstriction of coronary blood ve sels and
resulting decreased oxygen supply, may override
coronary autoregulation and produce the
cardiovascular toxic effects associated with this
drug7 •
Other potential theories that may explain the
cardiotoxic mechanisms of cocaine in addition to
acute
myocardial
infarction,
coronary
vasoconstriction, and arrhythmias, include platelet
aggregation 10 • 19 , contraction band necrosis 4 •20 ,
myocarditis2.4, and cardiomyopathy (see figure 1}10.2 1•

lcoCAINE j

T OXICOLOGY
Although toxic effects of cocaine may be
manifest in a variety of organ systems, including
cardiovascular, neurologic, peripheral vascular,
gastrointestinal, and musculoskeletal, the CNS
and cardiovascular systems are responsible for
most of the life-threatening complications seen.
Specific neurologic complications include agitated
delirium (intense paranoia) 14, cerebrovascular
accident (potentially involving cerebral infarction,
in tr acerebral hemorrhage, or subarachnoid
hemorrhage) 15 , and partial or generalized tonicclonic seizures 16 • Seizures have been suggested as
the single most lethal effect of cocaine toxicityt 7 •
Death in relation to cardiovascular complications,
can result from ventricular fibrillation or asystole
following doses as little as 20mg of parenterally
administered cocaine. Recently, an increase in
fatalities has been ascribed to cardiovascular and
neurologic complications•.
Blood levels of cocaine can be misleading. A
200-fold range of levels have been reported as
lethal 11 •
This is explainable given that
su sceptibility to the drug's toxic effects, as well as
i t s metabolism, varies among individuals 18 •
Therefore, cardiac and neurologic consequences,
however, are not limited to large doses of cocaine6 •
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ACUTE MYOCARDIAL INFARCTION

The etiology of acute myocardial InJury is
multifactoria 1• Cocaine's sympathomimetic effects
elicit an increase in myocardial work. Coupled with
a decrease in myocardial blood flow produced by
coronary vasoconstriction and impaired pump
activity, these toxic effects contribute to ischemia
and perhaps, infarction. The combination of direct
toxic effects of contraction bands and platelet
adhesiveness, predispose to focal myocardial injury
and, in the long-term, cardiomyopathy 21 •
Furthermore cocaine may directly depress
ventricular function in the absence of any acute
myocardial injury. Acute ventricular dysfunction
may occur as a result of sodium channel blockade.
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Problem

Solv ing

MEDICAL VOCABULARY
This section is designed to test and expand your knowledge of medical
terminology. How many items can you correctly define?
Scoring: [13-lS]=Superior knowledge, [10-12]=Abo e average, [8-9]=Adequate, [S-7]=Fair, [1-4]=Sub-par.

1.

a)
b)
c)
d)

Degloving:
debridement of the palmar epidermal layer
following burn injury;
intra-oral surgical exposure of the bony
mandibular regions;
removal of procedure gloves following
contamination of the surgical field;
post-operative anaesthesia! phenomenon
involving transient parasthesia of the upper
limbs;

6.
a)
b)
c)
d)
7.

a)

Xenophonia:
alteration in the quality of voice;
the adoption of a foreign voice due to
schizophrenic delusions;
c) the quality of sound produced by a non-native
speaker of a language;
d ) the auditory hallucination of a non-self voice
evident in schizophrenia;

b)
c)
d)

Zonesthesia:
a loss of feeling or sensation involving multiple
derma tomes;
area of focal numbness caused by local
anaesthetic;
a zone characterized by swelling and loss of
function caused by a zootoxin;
a sensation of constriction , as by a girdle;

b)
c)
d)

2.

a)
b)

3.

a)
b)
c)
d)

8.

a)

9.

a)
b)

4.
a)
b)

c)
d)
5.
a)

Miliary:
a form of hyperkeratinized epithelial cyst;
pertaining to a cutaneous condition with
retention of sweat;
characterized by lesions resembling millet
eeds;
a erythemic sign;

Butyroid:
trademark for a preparation of butacaine
sulfate;
b) an amino acid derivative of butyric acid;
c) an abnormal amount of saturated fatty acid
residues in sweat due to chemical imbalance of
the body;
d ) resembling or having the consistency of butter;

c)
d)
10.
a)
b)
c)
d)

Transfaunation:
genetic transformation in viruses;
genetic recombination of non-host D A with
host D A;
transfer of animal parasites from one host to
another;
Old English term for transformation;
Viraginity:
p eudohermaphrodi m resulting in an inability
to conceive;
a consequence of androgenization syndromes;
incapable of inducing o ulation;
a condition in which a woman has the sexual
feelings and mentality of a man;
Perionyx:
a relic of the eponychium persisting as a band
across the root of the nail during fetal
development;
situa ted about the nailbed;
a kind of hypopyon;
an activating area associa ted with the dorsad
region of the embryonic notochord;
Bubo:
a dome -shaped skin lesion with transient
surface vesiculations;
inflamed lymph node, particularly in the groin
or axilla;
the non-muscular component of the
bulbococcygeus muscle;
a disease caused by consumption of the
poisonous fruit of a tropical vine;
Fleckfeiber:
epidemic typhus;
intrinsic "trigger" to regulate diurnal rhythm;
a German department store;
a syndrome associated with a virulent pathogen
of unknown origin;
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Problem

Solving

11. Fragiform:
a)

b)
c)
d)

disruption of Haversian canal formation in
bone;
shaped like a strawberry;
general description of any friable lesion;
none of the above;

m
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12. Stomatomalacia:
a) any pathological condition of the mouth;
b) softening of tissue of the abdominal wall
c)
d)

Marcelle offers a complete range
of high quality skincare products
and cosmetics ...to care for
your skin simply, beautifully.

surrounding a colostomy /ileostomy opening;
a condition of body weakness;
abnormal softness of the oral structures;

•
•

----•• ...- ...
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13. Trichonodosis:
a)
b)
c)
d)

14. Meroacrania:
a)
b)
c)
d)

partly secreting;
a teratogenic consequence of organic mercury
exposure;
partial congenital fissure of the cranium which
extends into the cervical vertebrae;
congenital absence of part of the cranium;

15. Fourniere's Gangrene:
a)
b)
c)
d)

--

a fungal infection caused by species of
Trichophyton;
the condition in which hairs are split and
feather-like;
knotting of the hair as a result of inability of
new hairs to grow from their follicles;
any disease or abnormal growth of the hair;

necrosis of a digit secondary to the use of
epinephrine in a local anaesthetic preparation;
fulminating gangrene of the scrotum;
tracking of anaerobes fran a bite wound in the
hand;
gradual onset psychosis secondary to sle p
deprivation;

----

CLINICAL ASSISTANTS MEDICAL ONCOLOGY
Undecided about your future career?
Would you like more experience in general
medicine, particularly in the management of
patients with cancer?
Clinical assistants in medical oncology undertake care
of patients under the supervision of staff oncologists.
Full-time positions are available at the London Regional
Cancer Centre , and Medical Oncology Unit, St.
Joseph's Health Centre. You would join a junior staff of
3 clinical assistants, 2 medical oncology residents, and
rotationg resident staff (radiation oncology ,
haematology, gynaecology) . There would be
opportunities to participate in the postgraduate
education program . Weekend and evening call is
required (from home) not to exceed 1 in 6.
The starting salary is $71507, with an attractive benefits
package and 4 weeks paid holiday/year.
Qualifications:

MD or equivalent degree
General licence to practice in Ontario

Applications with curriculum vitae and names of two
references should be sent to:
Dr. Vivien Bramwell
Head, Medical Oncology
London Regional Cancer Centre
790 Commissioners Road, East
London, Ontario, Canada N6A 4L6
For further information, telephone
(519) 685 8639.
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ANSWERS

TO

MEDICAL

Solving

VOCABULARY

,...

1. Degloving:

b) The exposure of the bony mandibular anterior or
posterior regions by oral surgery.
2. Xenophonia:
a) Alteration of the accent and intonation of a
person's speech.
3. Zonesthesia:

d) A painful sensation of constriction, as of a
bandage bound too tightly, especially around the
waist, also known as girdle sensation.

8. Perionyx:
a) A relic of the eponychium persisting as a band
across the root of the nail, seen in the eighth month
of fetal life.
9. Bubo:
b) An enlarged and inflamed lymph node,
particularly in the groin or axilla, due to an
infection such as plague, syphillis, gonorrhoea,
lymphogranuloma venereum, and tuberculosis.
10. Fleckfeiber:

a) Epidemic typhus.
4. Miliary:
c) Characterized by lesions resembling millet
seeds, as in miliary tuberculosis.
5. Butyroid:
d) Resembling or having the consistency of butter.
Butyric acid is a four-carbon fatty acid found in
rancid butter.
6. Transfaunation:

c) Transfer of animal parasites from one host to
another.

11. Fragiform:
b) Shaped like a strawberry [L. fraga, strawberry].
12. Stomatomalacia:

d) Abnormal softening of the oral structures.
13. Trichonodosis:

c) A rare condition characterized by apparent or
actual knotting of the hair thought to be the result
of inability of new hairs to grow freely from their
follicles because of abnormal toughness of the
surrounding tissues.

7. Viraginity:

d) A condition in which a woman has the sexual
feelings and mentality of a man.

14. Meroacrania:
d) A congenital absence of part of the cranium.
15. Fourniere's Gangrene:
b) Fulminating gangrene of the scrotum.
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P r ob l em

So lvi ng

ANSWERS TO CASE STUDY
1. Was there any blood in the erne is or diarrhea?
ot in his emesis; he did not look at the diarrhea.
Did anyone el e eat the mushrooms? His wife only
had a teaspoonful full. (She was worried they were
not safe.) She has had a small amount of d iarrhes
and has thrown up twice.
2. He has not kept anything down for 12 hours
and is dehydrated. Start an IV and give him some
normal saline. It would be kind to also give him
some Gravol for the nausea. Because mushrooms
can cause renal and hepatic failure you need to do
some routine blood work including renal and liver
function tests and a PT / PTT.
3. Who knows. You would expect him to be
hypokalemic from all the diarrhea. Perhaps it was
from damaged liver cells. He need an EKG (look
for peaked T waves) and gases done. He is at risk
of going into v.fib unless his K promptly lowered
by driving it back into cells (gi e dextro e and
insulin, and bicarb) and by eliminating it (with an
ion-exchange resin such as Kayexalate).
4. Very worried. There are several different
groups of mushrooms . The clinical effect vary
with the type of toxin ingested. Con idering he got
sick more than 6 hours after he ate the mushrooms,
the se erity of the vomiting and diarrhes and that
his AST is already up, he probably ate Amanita sp.
Poisoning wi th this t ype of mushroom has a
mortality of 20-30%!

The following misconceptions in the treatment
of mushroom poisoning should be avoided.
1) Poisoning may be an allergic reaction or food
poisoning secondary to bacteria;
2) Poisoning may be secondary to pesticides
sprayed on the mushroom or to edible mushrooms
laced with drugs (like PCP);
3) All people ingesting mushrooms must become
ill·
4) Symptoms presenting after six hours can' t be
due to Amanitas ingestion;
5) Di charge of patients without follow-up despite
reco ery from GI symptoms when the e symptoms
occurred six hours post-ingestion;
6) As e sing toxin identification and considering
antidotes take precedence over theorie s of
supportive care;
I
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GUIDELINES
The purpose of the U.W.O. Medical Journal is to
rovide a single forum for original articles based
n clinical or research medicine of topical or
istoric relevance. Since the readership of the
ournal is interdisciplinary, articles published will
ttempt to reflect the wide range of medical
isciplines. The Journal will consider empirical,
heoretical, and research reviews. Book reviews will
so be considered. The Journal reserves the right to
efuse articles that do not comply with the
ournal's publication criteria.

ANUS CRIPT SUBMISSION: Each submission
ust include three (3) copies of the full manuscript
RIOR TO the submission deadline. Late
ubmissions will not be accepted for publication.
uthors are expected to submit the final revised
ersion of the manuscript on 3.5" computer
iskette along with three (3) copies of the
anuscript (the Journal prefers Apple Macintosh®
icrosoft® Word or Wordperfect® 5.1). All figures
filUSt be camera-ready and artwork must be black
and white.

TO

AUTHORS

AUTH ORSHIP: All medical stud ents and
members of the Faculty of Medicine of U.W.O. are
invited to submit manuscripts for publication.
Medical students are certainly encouraged to
collaborate with medical staff who specialize in the
medical sub-discipline being reported on.
Manuscripts will also be considered from medical
faculty (including interns and residents) from
universities and medical institutions other than

u.w.o.

MODES OF COMMUNICATION: Authors should
submit along with their manuscripts a cover letter
including a return address, telephone number, and
fax number (where available). The final revised
version of the manuscript on 3.5" compu t er
diskette should be sent (with (3) photocopies of the
manuscript) to:

The Editors
U. W.O. Medical Journal
Health Sciences Building;
University of Western Ontario
London, Ontario N6A-5Cl

MANUSCRIPT PREPARATION: Manuscripts
5ubmitted should be set with one inch margins and
typed single-spaced. Original research and review
articles should have an abstract that clearly states
the relevance of the article to the medical discipline
being reported on in no more than 150 words. This
dimension should be elaborated upon in the
introduction. Original research articles should have
experimental methods, results, and discussion
5ections that follow the introduction. Results and
discussion sections may be combined if
a.ppropriate. The discussion section should be
:oncise and focus primarily on the findings being
presented and their important implications.
A.uthors should rely on articles or information
published in recognized journal and sources.
References should be listed in numerical order and
within the text in the following format:

n

1. Manev H ., Favaron M., Guidotti A., & Costa E.

Delayed increase of ca++ influx elicited by
glutamate: role in neuronal death . Malec.
Pharmacal. 36:106-12 (1989).

fhe Journal reserves the right to edit articles to
:orrect grammatical or stylistic errors.
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